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SUMMARY 
Sickle cell disease (SCD) is the most common inherited blood disorder in the 
United States. SCD affects approximately 100,000 people domestically and an additional 
300,000 babies born globally every year. A collection of pathologies, including 
osteonecrosis (ON), osteoporosis, and osteopenia, known as sickle bone disease (SBD) 
are among the most common complications of SCD, which progresses from adolescence 
and occurs in 50% of individuals by age 35. Transgenic sickle mouse model studies have 
shown that increased osteoclast activity and reduced mesenchymal stem cell (MSC) 
differentiation into osteoblasts contributes broadly to pathological bone remodeling in 
SCD, but underlying cellular and molecular mechanisms are poorly understood. 
Sphingosine 1-phosphate (S1P), a type of sphingolipid, directs a wide array of cellular 
processes involved in bone homeostasis including directing MSCs towards an osteogenic 
lineage and modulating their migration. S1P also regulates osteoclastogenesis and is 
linked to the activity of cathepsin K (cat K), a protease secreted by osteoclasts to resorb 
bone. We have previously shown that dysregulated sphingolipid metabolism in SCD 
leads to increased S1P in sickle patients’ blood, plasma, and erythrocytes. Monocytes 
isolated from people with SCD are primed for inflammation and cat K proteolytic activity 
induction when binding to endothelial cells. Cat K-induced bone resorption mechanisms 
are implicated in bone dysfunction without SCD but have not been mechanistically linked 
to SCD osteopathologies. 
  The objective of this research is to investigate the relationship between 
sphingolipid metabolism and cathepsin activation in SCD. It is also the aim of this work 
to utilize sphingolipid signaling as a potential therapy for SBD. It is hypothesized that 
 xviii 
dysregulated sphingolipid metabolism leads to bone loss in SCD that is propagated by 
increased cathepsin activity and that bone loss can be mitigated by cathepsin inhibition. 
This study utilizes a transgenic mouse model to characterize the sickle bone phenotype 
and to test the effect of a cathepsin inhibitor on bone morphology. This research further 
utilizes a S1P analog in wild-type mice to investigate if mobilizing MSCs out of the bone 
marrow can aid in bone repair. Elucidation of how dysregulated sphingolipid metabolism 
contributes to increased proteolytic activity in SCD that leads to increased bone 
resorption will better inform clinical therapeutic strategies to prevent detrimental bone 









CHAPTER 1  INTRODUCTION AND SPECIFIC AIMS  
1.1 Introduction 
Sickle cell disease (SCD) is a genetic disorder affecting nearly 100,000 
Americans and millions worldwide [1]. In states of deoxygenation, the homozygous 
sickle mutation in β-globin (SS) causes polymerization of hemoglobin molecules into 
rigid fibers within erythrocytes, or red blood cells (RBCs), deforming them into a 
“sickle” shape. This membrane distortion impedes RBC passage through narrow blood 
vessels, leading to obstructed blood flow to tissues and organs known as vaso-occlusion. 
Vaso-occlusion can also be localized in the bone [2, 3]. Increased erythropoiesis and 
consequent marrow expansion in the long bones increase the frequency of bone infarcts 
in sickle patients. Pathological bone remodeling begins in adolescence [2, 4], progresses 
with increasing age, and presents in 50% of individuals by age 35 [5, 6]. To prevent the 
progression of bone and joint damage, bed rest and avoiding activities such as running or 
stair climbing are recommended, but these restrictions drastically reduce quality of life 
[7]. Surgical treatments, such as a total hip replacement (which can occur as early as age 
18), have an elevated risk of inducing complications [8, 9]. Although progress has been 
made in elucidating both acute and chronic dysfunction in several organ systems, the 
mechanisms and preventive therapeutic treatments for pathological bone remodeling in 
SCD, or sickle bone disease (SBD), have not been widely investigated. 
Dysregulation of sphingolipid metabolism may serve as a feed-forward 
mechanism that exacerbates SCD-associated pathologies. Sphingolipids are a structurally 
diverse class of membrane lipids that serve distinct functions in cell signaling. We have 
shown that due to the dynamic shape distortion of sickled RBCs, the activity of acid 
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sphingomyelinase (SMase), an enzyme that acts on the sphingolipid sphingomyelin, is 
increased in the blood, plasma, and erythrocytes of people living with SCD [10]. 
Moreover, this increase in sphingomyelin hydrolysis causes the increased production and 
of release of RBC-derived microparticles (MPs) in SCD. Once phagocytosed by 
osteoclastic precursors, sickled MPs (SS MPs) induce the secretion of osteoclastogenic, 
proinflammatory cytokines [10]. A connection between dysregulation of sphingolipid 
metabolism and bone pathology in SCD is bolstered by reports of increased plasma MPs 
in SS patients with osteonecrosis (ON) of the femoral head (OFNH) compared to SS 
patients without OFNH [11].  
Moreover, we have found that sphingosine 1-phosphate (S1P), a bioactive 
sphingolipid, is elevated in human SS blood, plasma, and RBCs [10].  Zhang et 
al. demonstrates that increased production of S1P contributes to erythrocyte sickling [12]. 
S1P regulates various cellular functions important to bone homeostasis such as 
mesenchymal stem cell (MSC) differentiation into osteoblasts and osteoclastogenesis 
[13-15]. Additionally, S1P production is linked to the expression of cathepsin K (cat K) 
in osteoclasts [16]. Cat K is the key bone resorptive enzyme secreted by osteoclasts.  
Monocytes isolated from people with SCD are primed for inflammation and cat K 
proteolytic activity induction when binding to endothelial cells [17]. Cat K-induced bone 
resorption mechanisms are implicated in bone dysfunction but have not been 
mechanistically linked to SCD osteopathologies. Lastly, mobilization of MSCs [13, 18, 
19] and hematopoietic stem cells (HSCs) from the bone marrow (BM) and into 
circulation are guided along the S1P gradient via signaling through 5 G-coupled receptors 
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(S1PR1-S1PR5) [20-22], and it is speculated that poor bone formation in SCD could be 
due to poor circulation of stem and progenitor cells to the site of bone infarcts [23].  
1.2 Research Objectives and Specific Aims  
The objective of this work is to investigate whether the disruption of sphingolipid 
metabolism in SCD induces hyper-proteolytic, bone resorptive activity through cat K. We 
also aim to utilize sphingolipid signaling in order to improve bone repair. The central 
hypothesis of this thesis is that dysregulated sphingolipid metabolism leads to bone loss 
in SCD that is propagated by increased cathepsin activity and that bone loss can be 
mitigated by cathepsin inhibition. The central hypothesis will be addressed with the 
following three specific aims: 
 
Aim 1. To characterize the transgenic sickle Townes mouse model for bone 
pathologies. The objective of this aim is to characterize bone pathology in female and 
male mice to determine the effect of SCD on skeletal development. The hypothesis of 
this aim is that SS mice show significant delays in skeletal maturation, and adult bones 
have significantly altered bone morphology and biomechanical properties compared AA 
and AS mice. We further hypothesize that bone pathology in SCD is sex dependent. 
Skeletal maturity will be assessed by examining the proximal femur epiphyseal fusion of 
3-and-5month old mice via micro-computed tomography (microCT). Analysis of the 
amount of calcified bone present will be determined with Mimics Materialise software. 
The cortical and trabecular bone morphology will be characterized at 3 and 5 months of 
age in male and female mice through microCT imaging. We will generate a multivariate 
data set with the 23 bone parameters from microCT software, using principal component 
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analysis to characterize which parameters most vary in sickle mice. This aim will 
elucidate how bone microarchitecture in the sickle cell mouse model varies over several 
months and how SBD affects each sex.  
 
Aim 2. To characterize link between sphingolipid metabolism and cathepsin-
mediated proteolysis to the bone loss in SCD. The objective of this aim is to investigate 
the nexus of sphingolipid metabolism, cathepsin proteolytic activity, and pathological 
bone remodeling in SS mice. Dysregulated sphingolipid metabolism in SCD causes an 
increase in the production of proinflammatory MPs. We believe the transport of MP-
derived signaling molecules to osteoclast precursors induces hyper-proteolytic, bone 
resorptive activity through the cat K pathway. We hypothesize that E-64, a cysteine 
cathepsin inhibitor, will decrease the proteolytic activity increased in SCD and will result 
in diminished bone loss. To this end, we will characterize sphingolipid expression in the 
blood of sickle mice through high throughput liquid chromatography- tandem mass 
spectrometry (HPLC-MS/MS). In order to investigate the effect of sphingolipid 
dysregulation on bone marrow progenitors that regulate bone homeostasis, lipidomic 
analysis on MSCs and flow cytometry characterization of osteoclast progenitors (OPCs) 
will be performed.  Sphingolipidomic analysis via HPLC-MS/MS will be performed on 
circulating, erythrocyte-derived SS MPs.  Moreover, the potential of proinflammatory, 
erythrocyte-derived SS MPs to induce cathepsin activity in monocytes will be evaluated 
through enzyme zymography for cat K and western blotting. Due to the bone loss present 
in SCD, we expect sickle animals will have increased cat K activity that can be mitigated 
over two months with daily injections of E-64. Cortical and trabecular bone morphology 
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in mouse femurs will be assessed with microCT imaging. Four point bending mechanical 
testing will be performed to determine the effect of E-64 treatment on the mechanical 
properties of the bones. We expect sickle animals receiving E-64 to have increased bone 
and mechanical strength. This aim will elucidate the relationship between sphingolipid 
metabolism and bone loss in SCD as well as determine if cathepsins are a viable target to 
treat SBD. 
 
Aim 3. To evaluate the role of S1P signaling in MSC migration and subsequent bone 
healing.  The objective of this aim is to determine if pharmacological inhibition of S1P 
receptor 3 (S1PR3), which has been shown to play a role in stem cell mobilization, can be 
used to mobilize MSCs to modulate bone repair. We hypothesize that VPC01091, a S1P1 
agonist and S1PR3 antagonist, will mobilize endogenous MSCs out of the BM and into 
circulation, which will result in accelerated bone healing. In this aim, S1PR3 knockout 
mouse model will be used to determine if there is an increase in the MSC population in 
the PB, as detected by flow cytometry. We will treat wildtype mice intraperitoneally with 
VPC01091 and assess via flow cytometry if MSCs are present within the PB following 
1.5, 3, and 24 hours after treatment. We will utilize an ectopic bone and critical size 
cranial defect model to evaluate VPC01091’s effect on new bone formation over the 
course of 6 and 8 weeks, respectively. Bone growth will be assessed by microCT imaging 
and histology. Characterization of cells recruited to the bone defect site will be assessed 
by flow cytometry. This aim examines the potential of pharmacological inhibition of 
S1PR3 to mobilize endogenous MSCs as a therapeutic strategy for bone fractures as well 
as chronic bone metabolic diseases such as SBD.  
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CHAPTER 2  LITERATURE REVIEW 
2.1 Sickle Cell Disease  
Sickle cell disease (SCD) is a genetic blood disorder caused by the substitution of 
valine for glutamic acid in the  subunit of the gene encoding for hemoglobin and affects 
approximately 100,000 Americans and millions worldwide [24]. While the annual 
prevalence of SCD in African Americans is estimated to be 1 in every 360 births, the 
global prevalence is estimated to be an astounding 400,000 annual births by the year 
2050. Moreover, approximately 1 in every 67 infants born in the United States are genetic 
carriers  [25]. In states of hypoxia in blood vessels, hydrophobic valine is subjected to the 
aqueous environment of erythrocyte cytoplasm [26]. This contact causes for sickle 
hemoglobin (HbS) to alter into rigid, rod-shaped fibers that disfigure the normal shape of 
red blood cells (RBCs) into a “sickle” conformation [27]. Loss of the bi-concave shape of 
erythrocytes limits deformation that is required to traverse the vasculature and leads to 
their entrapment in small vessels such as the capillaries, thus obstructing blood flow [26].  
This blockage produces one of the hallmarks of SCD: the vaso-occlusive, or pain, crisis. 
Vaso-occlusion can lead to several pathologies including chronic pain and inflammation, 
stroke, cardiovascular disease, organ failure, and eventually death [28, 29].  
SCD pathophysiology has been shown to affect both sexes differently. Men 
typically endure an increased frequency of pain crises following the age of 15, compared 
to women with SCD [30].  This difference could be attributed to multiple factors such as 
decreased nitric oxide availability in men that leads to increased infarction or that females 
with SCD express higher levels of fetal hemoglobin (HbF), which unlike HbS, does not 
polymerize in states of deoxygenation [30, 31]. In fact, male patients with SCD are only 
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expected to live up to the age to 42, while the life expectancy of female patients is 48 
years old [32]. With the variability of SCD symptoms being sex-dependent, it is 
imperative to study SCD complications separately in men and women.  
2.1.1 Treatment for Sickle Cell Disease  
 Even though the discovery for the mutation of SCD is a century old, there is 
currently only a minimal number of FDA-approved drugs for treatment. One such drug, 
hydroxyurea, aims to increase the production of HbF, which does not polymerize in states 
of hypoxia, in order to decrease vaso-occluison [33]. Endari, or L-glutamine, is the first 
drug approved for pediatric sickle patients and lowers SS RBC stiffness and sickling by 
reducing their oxidative stress [34]. The gold standard of care is blood transfusions, 
which are utilized to amplify the number of non-sickle erythrocytes in sickle cell patients 
and thus decrease the number of vaso-occulsions caused by RBC sickling. Due to iron 
overload, however, this treatment causes cardiovascular and hepatic damage, increased 
inflammation, and osteoporosis [35, 36]. Furthermore, transfusions and pain management 
cause costly hospitalizations for patients, leading to annual health care costs of more than 
$1.1 billion dollars in the United States [37]. While gene editing techniques such as 
engineered zinc finger nucleases have been studied to rectify the sickle-cell-anemia-
causing mutation for the substitution of the amino acid of glutamic acid to valine in the  
globin sub-unit of hemoglobin, bone marrow (BM) transplants are the only current 
remedy for SCD [38]. With SCD affecting mainly African Americans in the United 
States, (who only make up 13% of the population) finding a full-match donor is very 
challenging. Furthermore, BM transplants come with the potentially fatal risk of graft-vs 
host disease, in which the immune cells from the donated tissue attack the recipient’s 
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tissues/cells [39]. Finally, the pain that sickle cell patients suffer from and treatments for 
their various resulting underlying disorders, such has sickle bone disease (SBD), have not 
been properly addressed.   
2.2 Sickle Bone Disease  
Many hospitalizations of sickle cell patients are often due to vaso-occlusive 
crises. As sickled erythrocytes become unable to travel through narrow blood vessels, 
irremediable injury occurs to subsequent tissues and organs [26].  Being a highly 
vascularized connective tissue, bone is not immune from this damage, and often pain 
crises occur in the bone and joints of people with SCD. The prevalence of bone loss 
increases from 3% in adolescents to 50% in sickle cell patients over 35 as vaso-occlusive 
crises increase in frequency with age [4]. Bone and joint disorders including osteopenia, 
osteoporosis, osteonecrosis (ON), known collectively as sickle bone disease (SBD), are 
among the most common complications of SCD [40]. SBD can impact various parts of 
the skeleton with 30% of cases being present in the tibia/fibula, 25% in the femur, and 
21% of cases affecting the radius, ulna, and humerus [41]. Osteopenia, a precursor to 
osteoporosis, is characterized by loss of bone mineral density. In the case of osteoporosis, 
people with SCD experience approximately 6-21% reduction in bone mineral density in 
all bone regions due to BM hyperplasia, but it is quite frequently associated with 
vertebral collapse [42]. ON, which is the death of bone tissue, results from vaso-
occlusions that most commonly occur in the head of long bones. Nearly 41% of adults 
and 27% of children  with SCD have been found to have ON, particularly in the femoral 
or humeral head [2]. Without treatment, ON can produce constricted joint spaces, bone 
spurs, and eventual collapse of the femoral head within 5 years of onset [7, 43]. 
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Diagnosing and treating SBD remains difficult and insufficient. During the initial 
phase of vaso-occlusive crises, standard radiographs are unable to detect BM infarcts 
[43]. Other methods such as radioisotope bone scanning and MRI can detect infarcts in 
the acute phase; however, these methodologies are unreliable for developing accurate 
diagnoses. For instance, a BM infarct can be erroneously attributed to ON when a patient 
actually has osteomyelitis, or infection of the bone [41, 44]. Furthermore, dual-energy X-
ray absorptiometry (DXA) is the standard clinical metric to evaluate bone mineral density 
and assess the onset of osteoporosis. However, this metric’s results can be muddied with 
signal gleaned from surrounding muscle or other soft tissue [45]. Surgical treatments of 
SBD for distinct bone lesions, such as core decompression of the femoral head (early 
stage) or hip replacement (advanced stage) are performed at an average age of 26 in one 
study with 40% of the patients in their teenage years [8]. Those undergoing surgeries also 
have an elevated risk of inducing complications such as infection, congestive heart 
failure, and acute chest syndrome [8, 9]. As an alternative to delay or prevent surgical 
intervention, bed rest and avoiding activities such as running or stair climbing are 
recommended to prevent the progression of joint damage, but these methods drastically 
affect the quality of patient life [7]. Clearly, there is a need to investigate new therapeutic 
paradigms to develop more effective SBD treatments.  
2.3 Sphingolipid Metabolism  
2.3.1 Sphingolipid Metabolism Overview 
Sphingolipids are a structurally diverse class of membrane lipids that are 
composed of an 18-carbon amino-alcohol backbone, sphingosine (So), and are 
synthesized in the endoplasmic reticulum [46]. So and sphinganine 
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(Sa)/dihydrosphingosine, referred to as long-chain base sphingolipids, are the basic build-
ing blocks of sphingolipids in mammalian cells. The “sphingoid” backbone can be 
modified to produce a wide variety of sphingolipids with distinct functions in cell 
signaling and structural adaptations of biological membranes [47]. N-acylation of 
sphingosine by ceramide synthases (CerS) generates ceramide (Cer), a complex 
sphingolipid, whereas phosphorylation of the C1-hydroxyl group of So by sphingosine 
kinase (SK) produces sphingosine 1-phosphate (S1P) [48] (Figure 2.1). The fatty acyl 
structure of complex sphingolipids represents a major building block of Cer and other 
complex sphingolipids such as sphingomyelin (SM) and ceramide 1-phosphate (C1P), 
and a considerable number of variations exist in the structure of mammalian cell 
membranes. Among the complex sphingolipids, small differences in acyl chain length or 
unsaturation can be functionally consequential. For example, the production of different 
Cer species in cell membranes impacts membrane morphology and fluidity [49, 50]. As 
the hub of the sphingolipid metabolic network, Cer can serve as the precursor of more 
complex sphingolipids, such as glucosylceramides (GlcCers) and SMs. Owing to the 
smaller head group of Cer compared to SM, the hydrolysis of SM by acid 
sphingomyelinase (SMase) to produce Cer results in decreased membrane rigidity and the 
efflux of membrane lipids through the shedding of cell-derived microparticles (MPs) that 




Figure 2.1. Sphingolipid metabolism. Sphingolipids are synthesized de novo via the 
reaction between serine and palmitoyl CoA, which is facilitated by serine palmitoyl 
transferase. Due to the activity of several enzymes, sphingolipids are produced by many 
reversible and irreversible reactions. The enzyme SMase catalyzes the hydrolysis of 
sphingomyelin to create ceramide, the central hub of the sphingolipid metabolism 
network. Ceramide is further metabolized to yield sphingosine and sphingosine 1-
phosphate (Adapted from [10]). 
 
 
2.3.2 Sphingolipid Metabolism Involvement in Sickle Cell Pathology  
Dysregulation of sphingolipid metabolism may serve as a feed-forward 
mechanism that exacerbates SCD-associated pathologies.  Acid SMase secretion can be 
prompted by RBC death and prolonged inflammation, both processes which are 
hallmarks of SCD [52, 53]. Consequentially, erythrocytes obtained from donors 
homozygous for sickle (SS) hemoglobin have an elevated activity of acid SMase; this 
elevated activity also exacerbates SCD inflammation through the production of RBC-
derived MPs, which in turn induce increased  pro-inflammatory cytokine secretion and 
adhesion of myeloid cells [10]. Consequentially, MPs have been implicated in many 
processes in SCD including  coagulation [54] and vaso-occlusions [55].  Membrane 
curvature and associated increases in mechanical bending stresses in erythrocytes 
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activates SMase, reducing sphingomyelin and increasing ceramide [56].  This discovery 
further supports Awojoodu et al.’s previous findings that Cer is elevated in SS 
erythrocytes and that the activity of acid SMase is highest in the densest or irreversibly 
sickled fraction of SS erythrocytes [10]. Production of Cer has a direct effect on a wide 
range of cellular processes, and Cer is the direct precursor of So, which can be 
phosphorylated by either isoform of SK (SK1 or SK2) to produce S1P [46]. SK1 -
mediated increase of S1P has been shown to contribute to erythrocyte sickling [12].  
Furthermore, S1P is elevated in SS blood, plasma, and RBCs [10]. By activating S1P 
receptor 1 (S1PR1), S1P has been found to increase local and systemic inflammation that 
causes tissue damage and kidney failure [57]. With sphingolipids playing such a 
pervasive role in SCD, there is a strong motivative to investigate the role of S1P in sickle 
bone pathology.    
2.4 Sphingosine 1-Phosphate (S1P) 
2.4.1 S1P Overview  
 S1P is a bioactive sphingolipid that regulates various cellular functions such as 
migration, cell-cell adhesion, survival, and proliferation. These processes are controlled 
extracellularly through 5 G-protein coupled receptors (S1PR1-5) as well as can be 
initiated intracellularly by metabolized S1P [58-61]. This lipid intermediate also regulates 
cellular processes important to bone homeostasis such as mesenchymal stem cell (MSC) 
differentiation and osteoclast progenitor (OPC) circulation [14, 62].  
2.4.2 S1P’s Role in Bone Homeostasis   
 S1P is an osteoanabolic lipid. Marycz et al. recently showed how in vitro 
incubation of MSCs with S1P enhanced mineralized matrix formation during osteoblastic 
differentiation [63]. Moreover, S1P has been shown to promote osteogenic differentiation 
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but inhibit the adipogenic differentiation of multipotent stem cells [64]. This is further 
verified in an in vivo study where pharmacological or genetic inhibition of S1P lyase, an 
enzyme that degrades S1P, increases bone development and strength while 
simultaneously inhibiting adipogenesis [65]. This process is conducted through S1PR2 
signaling, whereby expression of genes that are involved in osteoblastogenesis such as 
Sparc (osteonectin) and Col1a (collagen type 1-) are upregulated while genes involved 
in adipocyte formation such as PPAR- are downregulated in primary murine osteoblasts 
treated with S1P. Additionally, S1PR2 activation downregulates the differentiation of 
osteoclasts by increasing the production of osteoprotegerin [65]. Osteoprotegrin binds to 
receptor activator of nuclear factor -  ligand (RANKL) to prevent it binding to the 
RANK receptor on OPCs that propagates osteoclast differentiation.  Consequentially, 
S1PR2 knockout mice are obese and have low bone mass.  Furthermore, Higashi et al. 
found that S1P upregulates runt-related transcription factor 2 (RUNX2) expression 
through S1PR2 signaling and leads to bone formation in vivo [14].  RUNX2 is a 
transcription factor that is responsible for pushing MSCs towards an osteogenic lineage 
[66]. Consequently, it has been shown that decreased expression of S1PR2 on MSCs 
decreases their differentiation into osteoblasts and is correlated to an increase in 
pluripotency factors including Nanog, Sox-9, and Oct-4 [13].  However, there is evidence 
that S1P can conduct bone formation through its S1PR3 receptor as well. FTY720 is an 
analog of S1P that binds to all 5 receptors, except for S1PR2. S1PR3 knockout mice 
suffer from osteopenia and reduced bone formation, but not increased bone resorption. 
Keller et al. found that FTY720 treatment increased bone formation in wild-type but not 
in S1PR3 knockout mice [67]. Furthermore, VPC23019, a S1PR1 and S1PR3 antagonist, 
inhibits the increased alkaline phosphatase production and mineralization seen in 
osteoblasts treated with S1P [16]. In a rat model of post-menopausal osteoporosis, 
FTY720 treatment of isolated MSCs increased osteogenic differentiation in comparison 
to sham and control groups [68].  Interestingly, one study in post-menopausal Korean 
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women found a correlation of high S1P levels in the blood to increased expression of the 
bone resorption marker C terminal telopeptide of type 1 collagen (CTX) and decreased 
bone mineral density [69]. However, this negative association was only found for some 
femoral locations such as the femoral shaft and not at the femoral neck or lumbar spine. 
Additionally, this was not a longitudinal study in which S1P plasma levels could be 
correlated with changes in bone mineral density over time. Still, Lee et al. makes the 
claim that higher circulating S1P can lead to bone resorption in women [69]. Weske et al. 
argues that increased S1P levels are more so indicative of the body’s response to 
diminishing bone quality to increase bone formation; in a German population study in 
which men and women data were reported together, S1P levels were not correlated to 
CTX and were positively correlated with the bone formation marker procollagen type 1-
N-terminal propeptide (PINP) [65]. With these varying results and S1P being increased in 
SCD, it is imperative to fully characterize the sickle bone phenotype.   
S1P also plays a role in the other side of bone homeostasis: bone resorption. 
Osteoclasts secrete S1P to act on themselves intracellularly as well as to aid in osteoclast-
osteoblast crosstalk. RANKL is secreted by osteoblasts and binds to RANK on OPCs to 
promote osteoclastogenesis. This pathway increases SK1 and S1P production in 
osteoclasts. However, once SK1 activity reaches a certain threshold, intracellular S1P 
attenuates further osteoclastogenesis and thus serves in a negative feedback loop [15]. 
However, osteoclast-secreted S1P can also bind to osteoblasts to promote further 
RANKL production and increase osteoclast differentiation [15, 16]. Additionally, S1P 
secretion by osteoclasts is further increased when cathepsin K (cat K), a protease that 
osteoclast secret to resorb bone, is inhibited [16]. Furthermore, S1P directs the migration 
of OPCs between the BM and blood. S1PR1 on OPCs directs them towards a higher S1P 
gradient. With RBCs being a S1P reservoir, S1P levels are higher within the peripheral 
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blood (PB) than in the BM. In a process deemed chemorepulsion by Ishii et al., S1PR2 on 
OPCs directs their chemotaxis towards lower S1P levels within the BM [70]. With S1P 
being increased in the blood of SCD patients [10], it is of interest of to investigate if the 
migration of OPCs is dysregulated in SCD.  
2.4.3 S1P Signaling Utilization for Mobilizing MSCs 
Stem and progenitor cells mobilized from the BM play a critical role in healing 
injured tissues. In fact, the production, mobilization, and recruitment of these cells are 
critical phases of tissue regeneration after traumatic injury [71-74]. Previous studies 
demonstrated that upon long bone fractures and other ischemic injuries, progenitor cells 
are mobilized and promote bone generation via vasculogenesis and osteoblastic 
differentiation [75-80]. Since endogenous stem and progenitor cells have been known to 
contribute to tissue repair, increasing their mobilization and recruitment at the defect site 
through pharmacological intervention has been studied to enhance healing. Systemic 
delivery of G-CSF or AMD3100, two potent stem cell mobilizing agents, has been shown 
to increase bone healing in fractures and calvarial defects, respectively [75, 76]. Recently, 
Fu et al.  utilized G-CSF in rabbits to mobilize MSCs into the blood to be harvested and 
cultured to treat ON [81].  Deng et al. mobilized MSCs with G-CSF into the PB and 
found that they can aid in repair of injured cerebral tissue [82]. However, in certain 
populations, such as cancer patients undergoing chemotherapy or sickle cell patients, G-
CSF has proven to be an ineffective or even life-threatening drug [83-85]. Furthermore, 
MSCs express the chemokine receptor 4 (CXCR4), which supports stem cells staying in 
the BM.  AMD3100, being a CXCR4 antagonist, is thus capable of interrupting this 
linkage and mobilizing MSCs into circulation [86, 87]. Antagonism of the stromal cell-
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derived factor-1 (SDF-1) receptor, CXCR4, by the small molecule AMD3100 is 
sufficient to cause rapid egress of  hematopoietic stem and progenitor cells (HSPCs) into 
the blood; however, AMD3100 may impair the cells’ ability to return to the niche since 
CXCR4 is necessary for homing and hematopoietic reconstitution [88] [89, 90].  
Toupadakis et al. showed that twice daily AMD3100 injections for 42 days negatively 
impacted bone healing in a mouse femur fracture model [91]. Consequently, Granero-
Molto et al. and Osturu et al. demonstrated that the CXCR4/SDF-1 pathway is necessary 
for MSCs to home to the bone and then differentiate into osteoblasts [92, 93]. Prolonged 
antagonism of CXCR4 impedes re-engraftment potential of MSCs into bone. Clearly 
there is a need to find another pathway to induce MSC mobilization. 
S1P chemoattracts hematopoietic stem cells (HSCs) and other progenitor cells and 
guides their egress from BM into the PB [21, 22].  S1PR1 and S1PR3 in particular, have 
been shown to have significant effects on stem cell mobilization and chemotaxis. 
SEW2871, an S1PR1 agonist, enhances the motility and mobilization of OPCs in vivo 
and regulates bone homeostasis [62]. S1PR3 activation on human endothelial progenitor 
cells (EPCs) resulted in phosphorylation of CXCR4 and enhanced SDF-1 mediated 
chemotaxis and homing to ischemic tissues [61]. Kimura et al. also showed that S1PR3 
activation with a small molecule analogue of S1P, FTY720, resulted in enhanced CXCR4 
function in HSCs in vitro and in vivo as well as enhanced homing and proliferation [94]. 
Additionally, Awojoodu et al. showed that BM-derived cells are recruited via S1PR3 to 
inflamed tissues and induce a reduction in proinflammatory cytokine secretion and 
microvascular remodeling [95]. According to Ogle et al., the use of VPC010191, a 
S1PR1 agonist and  S1PR3 antagonist, is capable of mobilizing HSPCs into circulation; 
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HSPCs cells pre-treated with VPC01091 had greater BM engraftment capacity in 
comparison to pre-treated AMD3100 cells [96].  Interestingly, Kong et al. demonstrated 
that the migration induced by S1P of human MSCs is conducted through S1PR1 and 
S1PR3 [18]. There is a need to further investigate the role that S1P signaling plays in 
MSC retention in the BM niche and subsequent migration.  
2.5 Cathepsins  
2.5.1 Cathepsin Overview  
A class of proteases known as cathepsins degrade intracellular and extracellular 
proteins [97, 98]. Cathepsins break peptide bonds optimally in acidic environments, such 
as in the lysosome of cells [97, 98]. These enzymes are also secreted and active in 
extracellular spaces such as the cytosol or within the cellular membrane [99]. There are 
several classes of cathepsins that can be differentiated from one another based on the type 
of amino acid located in their active site. Serine cathepsins include A and G; aspartic 
cathepsins include D and E [98, 100]. The most prevalent class, cysteine cathepsins, 
include K, B, C, W, S, V, X, H, F, L, and O [99]. Cysteine cathepsins have been shown to 
play a role in several aliments such as cancer [101], cardiovascular disease [102], 
atherosclerosis [103], rheumatoid arthritis [104], and osteoporosis [105, 106]. In the 
context of SCD, activated monocytes in people with SCD increase the activity of 
cathepsins K and V in endothelial cells, leading to pathological remodeling of the 
vasculature [17]. Additionally, cysteine cathepsins B and L are activated by acid SMase, 
an enzyme that enhances inflammation in SCD. [10, 107]. Inactive cathepsins or 
procathepsins become active through the removal of the N-terminal propeptide either by 
other mature cathepsins or proteases, such as in the aforementioned example of acid 
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SMase, or by self-proteolysis to unveil the active site [108]. Cystatin C, an endogenous 
inhibitor of cathepsins, is present in extracellular fluids such as blood and is elevated in 
sickle cell patients, especially those in crises [109, 110].   
2.5.2 Cathepsins’ Role in Bone Remodeling 
2.5.2.1 Cathepsin K 
 Osteoclasts are cells that resorb bone through the secretion of cathepsin K (cat K). 
In order to resorb bone, osteoclasts form a resorptive lacunae or pit between their ruffled 
border and the bone surface by attaching to the extracellular matrix proteins via 
v integrins [111, 112]. Cat K is transported from lysosomes and/or cytoplasmic 
vesicles and released into the resorption pit to degrade bone matrix [111, 112]. With 
bone’s organic matrix being 90% type I collagen, it is no surprise that cat K is the most 
effective mammalian collagenase [113]. This vigorous proteolytic activity can be 
attributed to cat K’s ability over other proteases to cleave the collagen triple helix as well 
as the cross-linked telopeptide sequences [99, 113]. Additionally, cat K is adept in 
degrading other proteins that compose the remaining 10% of bone matrix including 
fibronectin, biglycan, osteocalcin, bone sialoprotein, osteonectin, and osteopontin [114]. 
Cat K expression as well as osteoclastogenesis and osteoclast activation is regulated 
through RANKL binding to the RANK receptor on osteoclasts; this reaction induces the 
phosphorylation of transcription factor NFATc1 (nuclear factor of activated T-cells, 
cytoplasmic1) and thus ensues the activation of the cat K gene (CTSK) promoter. Other 
modulators of cat K secretion include TNF-, transcription factor Mitf, and INF- .  
2.5.2.2 Cathepsin K Inhibition  
 Cat K inhibition has been used as a therapeutic strategy to combat overactive 
osteoclasts in such orthopedic maladies such as osteoporosis and osteoarthritis. Despite 
successes in preclinical and primate models, many cat K inhibitors have failed clinical 
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trials [116]. For example, balicatib, a reversible cat K inhibitor, was found to increase 
cortical thickness (Cort.Th.) and decrease bone turnover in ovariectomized cynomolgus 
monkeys [117]. However, due to the accumulation of balicatib in lysosomes, off target 
effects occurred in the form of cat S inhibition as well as the accumulation of collagen 
deposits in the skin that lead to dermal lesions patients in a discontinued Phase II clinical 
trial [116, 118, 119]. Odanacatib, a selective cat k inhibitor, increased the femoral neck 
bone mineral density and improved the biomechanical strength of bone in ovariectomized 
rhesus macaque monkeys [120]. Moreover, odanacatib was found to increase the bone 
mineral density by at least 4% in the hip and femoral neck of post-menopausal women in 
Phase II clinical trials [121]. Conversely, Phase III trials were discontinued due to the 
increased risk of  patients developing stroke [122]. Likewise, there is clinical evidence 
that suggests complete cat K inhibition is not such a favorable outcome. Pycnodysostosis 
is a rare recessive disorder in humans in which mutations in CTSK lead to increased bone 
mineral density, but also cause brittle bones that are at an increased risk for fracture [117, 
123].  Furthermore, although cat K is the most abundant cathepsin in osteoclasts, there is 
evidence that other cysteine cathepsins contribute to bone resorption.  In mice, Hill et al. 
demonstrated that inhibitors for cat B and cat L inhibit bone resorption [124].  Ishibashi 
et al. has shown expression of cathepsin B, L, S in human osteoclasts [125]. Furthermore, 
Park et al. utilized enzyme zymography to establish the presence of activity of cat K, S, 
L, and V in human macrophages and osteoclasts [126].  These finding can be explained 
by the fact that cathepsins L, V, and S, similar to cat K, are collagenases [99, 113]. In 
fact, Everts et al. discovered that the broad cysteine cathepsin inhibitor, E-64, 
significantly increased the amount of non-digested bone matrix of mouse long bones 
explants, while the specific cat K inhibitors Z-Gly-Pro-Gln-VS-Ph and Z-Gly-Pro-Leu-
CHO had no significant effect on bone resorption [127]. With these results, E-64 can be 
utilized as a useful tool in discerning if cysteine cathepsins are an effective target for 
bone disorders, such as SBD.  
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CHAPTER 3  Extensive Characterization of the Sickle Bone 
Phenotype   
3.1 Introduction 
Sickle cell disease (SCD), which affects approximately 100,000 Americans, is a 
genetic hematological disorder caused by a single mutation in the -subunit of the gene 
encoding for hemoglobin [24]. In states of hypoxia, this mutation causes hemoglobin to 
transform into rod-shaped polymers and consequently distort erythrocytes, or red blood 
cells (RBCs), into a “sickle” shape. This membrane deformation causes erythrocytes to 
lose their flexibility and become trapped in small capillaries and arteries [26]. This vaso-
occlusion blocks blood supply to downstream tissues and is often associated with 
acute/chronic pain, frequently in the bone and joints. In addition, the vascular blockages 
can lead to potentially fatal pathologies such as irreversible organ damage, chronic 
inflammation, coronary/peripheral artery disease, ischemic and transient ischemic attack 
(TIA) stroke, and myocardial infarction [28, 29]. Bone and joint disorders including 
osteonecrosis (ON), osteoporosis, osteopenia, known collectively as sickle bone disease 
(SBD), are among the most common complications of SCD [40]. Nearly 41% of adults 
with SCD have ON, particularly in the femoral or humeral head [2]. Joint destruction in 
the femoral head leads to bone infarctions at the proximal epiphyseal plate [128]. As this 
region supports the greatest amount of weight-bearing forces, the anterior superior 
portion of the femoral head is frequently susceptible to collapse [129]. Within the 
proximal femur or hip, a process known as epiphyseal plate fusion, which occurs at the 
end of puberty in humans and by 6 months in mice, is essential for the joint to be able to 
withstand load-bearing forces and to prevent deformation during skeletal development 
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[130, 131]. During this process, an area known as the physis (depicted in Figure 3.1) that 
contains proliferating chondrocytes becomes senescent and is resorbed and replaced with 
ossified bone [130].  Epiphyseal fusion is a marker of skeletal maturity, and premature 
closure of the epiphysis is speculated to be the cause of growth retardation in children 
with SCD [132, 133]. Therefore, there is a need to characterize this process in SCD as the 
process of epiphyseal fusion is crucial to the structural integrity and skeletal development 
of the femoral head. 
Recent studies utilizing a transgenic sickle cell mouse model found that 
detrimental structural modifications to the microarchitecture of trabecular and cortical 
bone in SCD progresses over time and worsens with age [45, 134]. The trabecular bone 
in the microarchitecture of the femoral neck changes with age, including decreased 
number of trabeculae and a more rod-like structure.  These changes cause the femoral 
neck to be susceptible to fracture, an injury common in SCD patients [135, 136]. These 
aforementioned sickle mouse studies mainly focused on the knee joint or distal femur and 
do not characterize the trabecular bone in the hip joint or proximal femur. Therefore, in 
this work we made the novel characterization of the trabecular bone within the proximal 
femur in the sickle Townes transgenic mouse model.  
Furthermore, previous studies have either focused on one sex when using 
transgenic mouse models to investigate SBD [45, 134] or reported combined observations 
and data from both sexes [137]. It has been well established that bone morphometry can 
vary in humans, depending on sex and age. For instance, aging in men leads to weaker 
trabecular bone due to reduced trabecular thickness (Tb.Th.), while trabecular bone 
fragility in older women is due to the loss of trabecular plates [138]. One previous study 
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suggested that age and sex may play a role in SBD [139]. Furthermore, the standard 
clinical measurement of bone health, which is bone mineral density, varies in people with 
SCD due to age and sex [2, 140-142]. Since sex and age both influence bone physiology, 
this study sought to further characterize the sickle bone phenotype of male and female 
mice during bone development at three and five months in the Townes SCD mouse 
model.  
In this work we characterized bone development and the sickle bone phenotype 
through Mimics Materialise and micro-computed tomography (microCT) analysis of femurs 
from 3 and 5-month-old male and female mice. Homozygous sickle (SS) mice were 
compared to heterozygous sickle (AS) and homozygous non-sickle (AA) mice in regard to 
their proximal epiphyseal fusion and bone microarchitecture. We demonstrate for the first 
time that SCD delays skeletal maturity, SBD implements bone loss in different anatomical 
areas in male and female mice, and that trabecular morphology is the most important aspect 
in characterizing the sickle bone phenotype. 
3.2  Materials and Methods 
3.2.1 Animals  
Animal procedures and animal care protocols were performed in accordance and with 
approval from the Georgia Institute of Technology Animal Care and Use Committee. We 
utilized the Townes sickle transgenic mouse model (B6; 129-Hbatm1(HBA) Tow Hbbtm2 
(HBG1, HBB*) Tow/Hbbtm3 (HBG1, HBB) Tow/J) from Jackson Laboratories [143]. The 
genotype of the Townes mice was determined through Native polyacrylamide gel 
electrophoresis (PAGE) of their blood obtained via the tail vein. Femurs from 3 and 5-month 
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old male and female mice were isolated for microCT, Mimics Materialise, and histology. The 
bones were stored at -20C wrapped in gauze until time of evaluation.    
3.2.2 MicroCT Analysis  
Bone tissue mineral density (BMD) density and cortical and trabecular bone 
morphology within the femurs of 3-and 5-month-old male and female mice were 
examined by microCT imaging (μCT 40, Scano Medical, SUI) as previously reported 
[45, 144]. The mid diaphysis (1mm region at femur mid-point, 66 slices), distal epiphysis 
(0.32 mm in length distal from the growth plate, 25 slices), and femoral neck (44 slices 
extending distally from the proximal physis) were scanned at 12 um isotropic voxel size. 
Each section of interest is depicted in Figure 3.1. The analysis settings were as follows: 
55kVp voltage, 144uA current, and a medium resolution (1024 X 1024-pixel image 
detection matrix). Cortical and trabecular bone were separated in each region utilizing an 
auto-contorting program, with additional manual adjustments for proper boundary 
allocation [145]. Mineralized and soft tissue were distinguished within the mid diaphysis, 
distal epiphysis, and femoral neck using a Gaussian noise filter of 0.8, support of 1, and 
thresholding bone at 205-1000 mg hydroxyapatite (HA)/cm3, 62-1000 mg hydroxyapatite 
(HA)/cm3, and 211-1000 mg hydroxyapatite (HA)/cm3, respectively.  
Utilizing direct distance transformation algorithms in Scanco software [144, 146], 
we measured the cortical bone area (BA), total area (TA), cortical bone area fraction 
(BA/TA), and cortical thickness (Cort.Th.) for the mid diaphyseal region. For the 
trabecular bone in the distal epiphyseal and femoral neck regions, we additionally 
measured trabecular spacing (Tb.Sp.), trabecular thickness (Tb.Th.), trabecular number 
(Tb.N.), trabecular connectivity density (Conn.Den.), bone volume (BV), total volume 
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(TV), bone volume fraction (BV/TV), and structure model index (SMI). A blinded 
investigator assessed all scans.    
 
Figure 3.1. Femoral bone schematic. Diagram of microCT image of femoral bone with 
labeled areas analyzed by microCT. 
 
 
3.2.3 Mimics Materialise Analysis  
MicroCT images from male and female mice 3-and 5-months of age were used to 
reconstruct the first 5mm of the proximal femur. Mimics Materialise 15.0 (Leuven, 
Belgium) was used to generate a segmentation mask with a minimum threshold of 3070 
Housefield units, a value recommended by the software. For each mask a cuboidal region 
was manually segmented from the epiphysis in the femoral head and used to reconstruct a 
3D model. Porosity (%) was calculated from the reconstructed models using tools in 
Mimics. Bone volume fraction (%) was then calculated from porosity using the following 
equation:  
𝐵𝑜𝑛𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛(%) = 100 − 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (%) 
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3.2.4 Histology 
Femurs were harvested, fixed in 10% neutral buffered formalin for 24 hours at 
4oC, and decalcified using a formic acid decalcifying solution (Immunocal, StatLab, 
McKinney Tx) for 3 hours at room temperature. The bones were embedded in paraffin 
and the 5-month-old femoral heads were sectioned for hematoxylin and eosin (H&E) 
staining.  Bone sections were mounted with xylene mounting media (Thermo-Fisher) and 
visualized under a bright field microscope.  
3.2.5 Data Analysis and Statistical Comparisons 
By utilizing MATLAB software (Natick, MA), principal component analysis 
(PCA) was utilized on 23 bone parameters generated with microCT.  Principal 
components (PC) were generated, with the PC1 depicting the greatest percentage of data 
variance and PC2 (statistically independent from PC1) depicting the next utmost 
percentage of data variance. The microCT data was prepared in a matrix for each age (3 
and 5 months) with bone parameters in rows, and the individual mice in the first column 
separated by sex and genotype. Correlation coefficients between BV/TV and mouse body 
weight bone were produced with GraphPad Prism (La Jolla, CA). 
 Statistical comparisons were performed utilizing GraphPad Prism. The resulting 
analysis is conveyed as mean ± standard deviation (SD). Two-tailed t-test was used for 
column analysis. For grouped analyses, one-way ANOVA with Tukey’s post-test for 
multiple comparisons was utilized. For grouped analyses comparing data between 
genotype and age, two-way ANOVA with Tukey's multiple comparisons test was used. A 
p-value less than 0.05 was considered statistically significant.  
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3.3 Results 
3.3.1 SCD delays epiphyseal plate fusion  
Femoral microCT scans of 3- and 5-month-old male and female mice 
demonstrated a difference in proximal epiphyseal plate fusion among ages and genotype 
in the male mice, with no discernable differences in female mice. Based on previously 
reported results, we expected by 5 months to see fusion occur only in the male mice and 
not the females [130] . By 5 months of age, plate fusion (indicated by the appearance of 
hardened bone) occurs as anticipated for AA and AS male mice, but not for SS males 
(Figure 3.2A). As expected, epiphyseal plate fusion did not occur at 3 or 5 months for 
female mice regardless of genotype (Figure 3.2A). To confirm these observations, we 
quantified the bone volume fraction (BV/TV), which is the percent of mineralized bone 
per volume of sample, of the proximal epiphysis through Mimics Materialise. The 
BV/TV was significantly decreased in SS males (54.86  5.5%) in comparison to AA 




Figure 3.2. Epiphyseal plate fusion in the femoral head is age, sex, and genotype 
dependent. (A) Proximal femur microCT scans of male and female Townes mice at 3 
(top) and 5 (bottom) months. Arrow indicates epiphyseal fusion. Mimics Materialise 
analysis of bone volume fraction in the proximal epiphysis of the femur in (B) male and 
(C) female mice at 3 and 5 months (n=4-6 mice per group). AA=black, AS=gray, SS=red. 
Data expressed as mean ± SD. Statistical significance, * p< 0.05, determined by two-way 
ANOVA with Tukey’s post-hoc test, scale bar 1mm.  
 
 
Based on previous observations made in C57BL6 mice  [130], we expectantly observed 
no epiphyseal fusion in the distal epiphysis of the femurs, with no discernable differences 
between genotype, sex, or age (Figure 3.3).  
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Figure 3.3. Epiphyseal plate fusion does not occur in the distal femur. MicroCT scans 
of male and female mice at 3 (top) and 5 (bottom) months that display no epiphyseal 




H&E staining of SS male mice indicated that the proximal epiphyses were still in the 
senescence phase of epiphyseal plate fusion, characterized by the diminished presence of 
hypertrophic chondrocytes, rather than the state of fusion that is expected by 5 months 
(Figure 3.4A). For female mice, each genotype’s proximal epiphysis remained in the 





Figure 3.4. Histological staining of proximal epiphysis of the femur. Hematoxylin and 
eosin staining of (A) male and (B) female 5-month old proximal epiphysis. Complete 
resorption of the physis and epiphyseal fusion in AA and AS male mice occur by 5 
months, while SS males and all three genotypes of female mice remain in the senescence 
stage, indicated by diminished presence of proliferating chondrocytes. Scale bar 100um 
for 5X and 20 um for 63X images.  
 
 
MicroCT analysis of 12-month old SS male mice did show evidence of epiphyseal fusion 
(Figure 3.5A), further confirmed by their proximal epiphysis BV/TV trending towards 
being increased in comparison to 3- and 5-month SS males (Figure 3.5B). This data 
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suggests that SCD does not prevent ossification of bone but delays it. Additionally, we 
determined that epiphyseal BV/TV is significantly positively correlated to mouse body 
weight in AA (r= 0.9769, p= 0.0231) and AS (r=0.8793, p=0.0494) mice; however, there 
was no correlation in SS males (r=0.03971, p=0.9495) (Figure 3.5C). This further 
suggests a delay in overall growth and skeletal development due to SCD. Interestingly, 
the BV/TV of female AA (r=0.0074, p=0.9906) and AS (r=0.5185, p=0.4815) mice either 
had no correlation or were poorly positively correlated to body weight, respectively, 
while the BV/TV of female SS mice (r= -0.8029, p=0.1018) were negatively correlated to 
body weight (Figure 3.5D). 
 
Figure 3.5. SCD delays epiphyseal fusion and skeletal growth. (A) Micro-CT scans of 
12-month-old SS male mice that display epiphyseal plate fusion. (B) Mimics Materialise 
analysis of BV/TV of the proximal epiphysis in SS male mice at 3, 5, and 12 months 
(n=2-5 mice per group). Correlation plots for 5-month old (C) male and (D) female mice 
between BV/TV and mouse body weight. AA=black, AS=gray, SS=red (n=4-5 mice per 
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group). Data expressed as mean ± SD. Statistical significance, * p< 0.05, determined by 
correlation, scale bar 1mm.  
 
3.3.2 Sickle trabecular bone morphology varies with sex  
 Due to the differences in epiphyseal fusion between genotypes for male mice, we 
further analyzed the proximal femur and characterized the trabecular bone in the femoral 
neck via microCT. SCD did not have an effect on male trabecular bone, which can be 
visually seen in Figure 3.6A, as the overall trabecular structure and thickness is similar 
across genotypes.  Trabecular thickness (Tb.Th.) (48% increase in SS) and BV/TV (65% 
increase for SS) increase from 3 to 5 months while the structure model index (SMI) 
(1.173 to -0.63 for SS) decreases from the same time points for male mice of all three 
genotypes (Figure 3.6B-D). The latter indicates that over time the trabecular bone in the 
femoral neck in male mice changes to more concave morphology. Interestingly, SCD did 
have a negative effect in a 15% reduction of Tb.Th. in the femoral neck of SS female 
mice at 5 months in comparison to AA (Figure 3.6B). Bone mineral tissue density (BMD) 





Figure 3.6. Trabecular bone in the femoral neck increases in male mice with age. (A) 
Representative 3D heat maps of trabecular morphology in the femoral neck region of the 
proximal femur in AA, AS, and SS 3 (top) and 5 (bottom) -month-old male and female 
mice. A pseudocolor scale of blue (0 mm) to red (0.09 mm) depicts trabecular thickness. 
(B-D) Trabecular bone parameters generated by microCT scans for male (top) and female 
(bottom) including (B) trabecular thickness, (C) bone volume fraction, (D) structure 
model index and (E) bone tissue mineral density. AA=black, AS=gray, SS=red. Data 
expressed as mean ± SD. Statistical significance, * p< 0.05, determined by two-way 
ANOVA with Tukey’s post-hoc test, n=4-6 mice per group, scale bar 100 μm. 
Abbreviations: Tb.Th., trabecular thickness; SMI., structure model index; BMD, bone 





 The aforementioned reduction in proximal Tb.Th. in SS females is also present in 
the distal epiphyseal region, which is depicted in Figure 3.7A. Female SS Tb.Th. is 
decreased in comparison to AA mice at 3 and 5 months (Figure 3.7B). Of the female 
mice, only the AA genotype sees an increase (16%) in Tb.Th. from 3 to 5 months (Figure 
3.7B). Conversely, male AS and SS Tb. Th. increases 20% and 26% with age, 
respectively (Figure 3.7B). This suggests that sickle trait and SCD results in reduced 
trabecular bone growth with age only in female mice. Furthermore, the interconnectivity 
of the trabecular bone decreases 37% and 18% with respect to age for AS and SS 
females, respectively (Figure 3.7C). Interestingly, trabecular spacing (Tb.Sp.) is reduced 
up to 10% in SS females at both time points in comparison to controls, indicating that by 
5 months the trabeculae are close together, but do not compose as well as a connected 
structure (Figure 3.7C-D). The connective density (Conn. Den.) of AS and SS mice 
decreases 35% and 21% from 3 to 5 months for males as well, respectively (Figure 3.7D). 
However, no significant differences for Tb. Sp. were found for male mice (Figure 3.7C), 
suggesting a difference in trabecular morphology between SS males and females. This 
difference is further demonstrated in the BMD of SS female mice being reduced up to an 
astounding 79% at 5 months in comparison to AA and AS mice, while the BMD in SS 
male increases 8% with respect to age (Figure 3.7E).    
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Figure 3.7. Trabecular bone in the distal epiphysis is reduced in 3- and 5-month 
female SS mice. (A) Representative 3D heat maps of trabecular morphology in the 
epiphyseal region of the distal femur in AA, AS, and SS 3 (top) and 5 (bottom) -month-
old male and female mice. A pseudocolor scale of blue (0 mm) to red (0.09 mm) depicts 
trabecular thickness. (B-E) Trabecular bone parameters generated by microCT scans for 
male (top) and female (bottom) including (B) trabecular thickness, (C) connective density 
(D) trabecular spacing, and (E) bone mineral density. AA=black, AS=gray, SS=red. Data 
expressed as mean ± SD. Statistical significance, * p< 0.05, determined by two-way 
ANOVA with Tukey’s post-hoc test, n=4-6 mice per group, scale bar 100 μm. 
Abbreviations: Tb. Th., trabecular thickness; Tb. Sp., trabecular spacing; Conn. Density, 
connective density; BMD, bone mineral density.  
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3.3.3 Cortical bone is decreased in sickle mice  
 With cortical thickness (Cort. Th.) being a main contributor to bone strength 
[147], we also analyzed the cortical bone in the murine femurs within the mid diaphyseal 
region. SS femurs exhibited up to 27% in reduction of Cort. Th. in comparison to AA and 
AS genotypes at 3 and 5 months for both sexes (Figure 3.8B), which is visually indicated 
by more red being present in the 3D renderings of the area (Figure 3.8 A). However, 
Cort. Th. was found to increase up to 29% from 3 to 5months for all three genotypes for 
males and 16% for AA females (Figure 3.8B). This suggests that sickle trait and SCD 
subdues cortical bone growth with age only in female mice.  This distinction is further 
apparent in which again only AA female mice had a significant increase (16%) in BMD 
with age (Figure 3.8C). Furthermore, BMD was reduced up to 5% in SS male and female 
mice in comparison to wild-type and/or sickle trait at 3 and 5 months (Figure 3.8C). 
Mineralized tissue present, or bone area (BA) was also reduced up to 33% in SS male 
mice at 3 and 5 months in comparison to controls, but only significantly reduced (21%) 
for female mice at 5 months (Figure 3.8D). Similarly, bone area fraction (BA/TA) 
decreases up to 25% in SS mice of both sexes in comparison to AA and AS at both 3 and 
5 months. Interestingly, SS male mice BA/TA increases 18% from 3 to 5 months, but not 
to the level of AA or AS (Figure 3.8E).  
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Figure 3.8. Cortical bone deficiency in SS male and female mice persists at 3 and 5 
months. (A) Representative 3D heat maps of cortical thickness in the mid diaphyseal 
region in AA, AS, and SS 3 month (top) and 5 month (bottom) -month-old male and 
female mice. A pseudocolor scale of blue (0 mm) to red (0.2mm) depicts cortical 
thickness. (B-E) Cortical bone parameters generated by microCT scans for male (top) and 
female (bottom) mice including (B) cortical thickness, (C) bone tissue mineral density, 
(D) bone area, and (E) bone are fraction. AA=black, AS=gray, SS=red. Data expressed as 
mean ± SD. Statistical significance, * p< 0.05, determined by two-way ANOVA with 
Tukey’s post-hoc test, n=4-6 mice per group, scale bar 100 μm. Abbreviations: Cort. Th., 






3.3.4 Principal component analysis of microCT measurements on mouse femurs  
Since microCT analysis produces large multivariate datasets, we used 
unsupervised principal component analysis (PCA) to determine exactly what bone 
parameters contribute to the variability in the data we observed in Figure 3.6, Figure 3.7, 
and Figure 3.8. We wanted to also elucidate if age, genotype, or gender matter most in 
differences in bone morphology in the Townes mouse model. Figure 3.9A-B shows the 
two-dimensional (2D) principle component (PC) scores of each animal and the microCT 
parameters that contribute to each animal’s placement within the 2D PCA space. The first 
two PCs account for 62.48% of the variability in the data. There is very little observable 
clustering in the 2D renderings (Figure 3.9A-B). This indicates a need to further analyze 
the data with more separation.   
 
 
Figure 3.9. Unsupervised PCA of trabecular and cortical bone parameters of male 
and female mice at 3 and 5 months. (A) 2D scores plot of bone parameters for male and 
female AA, AS, and SS mice at 3 and 5 months. (B) 2D loadings (weight coefficients) 
plot of the 23 input variables in the reduced principal component space. Input variables 
are the following: mid diaphysis cortical bone- bone area, total area, bone area fraction, 
bone mineral density, cortical thickness; distal epiphysis and femoral neck trabecular 
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bone- bone volume, total volume, bone volume fraction bone mineral density, trabecular 
thickness, trabecular spacing, trabecular number, connective density, structure model 
index. N= 4-6 mice per group. Abbreviations: PCA, principal component analysis; F.N., 




We repeated PCA on the bone but instead this time we attempted to see if 
clustering of the data occurred when we separated the data based on age. Contrasting 
with the earlier PCA, there was clustering of the data based on genotype and gender. 
Figure 3.10A-B and Figure 3.11A-B show the 2D scores of each animal and the microCT 
parameters that contribute to each animal’s placement within the 2D PCA space. For 3-
month-old mice, the first two PCs account for 55.3% of the variability in the data, while 
they account for 62.69% for the 5-month-old mice. The data generally clustered by 
genotype, with the SS animals separating from AA and AS animals (Figure 3.10A, Figure 
3.11A). This suggests that genotype is the main contributor to differences we observed in 
the bone in Figure 3.6, Figure 3.7, and Figure 3.8.  
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Figure 3.10. Unsupervised PCA of cortical and trabecular bone parameters of male 
and female mice at 3 months. (A) 2D scores plot of bone parameters for male and 
female AA, AS, and SS mice at 3 months. (B) 2D loadings (weight coefficients) plot of 
the 23 input variables in PC1. Top components separating sickle samples are depicted in 
red. (C-E) Top three parameters in PC1 for 3-month-old males (top) and females 
(bottom) including (C) distal epiphyseal connective density, (D) femoral neck SMI, and 
(E) distal epiphyseal SMI.  Input variables are the following: mid-diaphysis cortical 
bone- bone area, total area, bone area fraction, bone mineral density, cortical thickness; 
distal epiphysis and femoral neck trabecular bone- bone volume, total volume, bone 
volume fraction bone mineral density, trabecular thickness, trabecular spacing, trabecular 
number, connective density, structure model index. Statistical significance, * p< 0.05, 
determined by one-way ANOVA with Tukey’s post-hoc test, n=4-6 mice per group. 
Abbreviations: PCA, principal component analysis; F.N., femoral neck; Ep., Epiphysis; 




 When we plot PC1 vs PC2 for 3-month-old mice, we see that the SS male and 
female animals separated from the AA and AS groups primarily along PC1, with both 
genders clustering into their own groups (Figure 3.10A). This separation is due to several 
parameters that are in PC1, including, Conn. Denn. (epiphysis and femoral neck), SMI 
(epiphysis and femoral neck), epiphysis Tb.N., femoral neck TV, and femoral neck 
Tb.Sp. (Figure 3.10B). In the loading parameters contributing to negative PC1 scores, we 
see a similar pattern for significant differences among genotypes in the males and 
females for epiphysis Conn. Den. (Figure 3.10C) and femoral neck SMI (Figure 3.10D). 
However, with epiphyseal SMI (Figure 3.10E), SS males have an increased SMI in 
comparison to wild-type and trait. This difference, however, is not seen in females. This 
indicates that SS males at 3 months are reaching more rod-like architecture in the distal 
trabecular bone. This is indicative of accelerated ageing and deterioration in bone 
structure [148]. In the AA and AS groups, female animals separate from the male animals 
along PC2, further indicating the need to study the bone in all three genotypes separately 
by sex (Figure 3.10A). The PC1 vs PC2 plot for 5-month-old mice reveals that the SS 
animals cluster away from the wild-type and trait groups along both PC1 and PC2. This 
separation is due to several parameters including, Conn.Den. (epiphysis and femoral 
neck), and epiphysis SMI (Figure 3.11A-B). For these parameters, SS Conn. Den. in the 
epiphysis is increased in female mice (Figure 3.11C) but is increased in SS male mice in 
the femoral neck (Figure 3.11D). This demonstrates that the sickle trabecular bone 
morphology is different depending on the region and gender, further supporting the 
results depicted in Figure 3.6 and Figure 3.7. Epiphysis SMI was not significantly 
different among the genotypes for males and females. It is interesting however that some 
male AS mice have negative SMI, indicating a concave trabecular morphology (Figure 
3.11E). Finally, as seen with three-month animals, AA and AS males separate from their 
female counterparts along PC2 (Figure 3.10A, Figure 3.11A).   
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Figure 3.11. Unsupervised PCA of cortical and trabecular bone parameters of male 
and female mice at 5 months. (A) 2D scores plot of bone parameters for male and 
female AA, AS, and SS mice at 5 months. (B) 2D loadings (weight coefficients) plot of 
the 23 input variables in the reduced principal component space. Top components 
separating sickle samples are depicted in red. (C-E) Top three parameters in PC space for 
5-month-old males (top) and females (bottom) including (C) distal epiphyseal connective 
density, (D) femoral neck connective density, and (E) distal epiphyseal SMI. Input 
variables are the following: mid-diaphysis cortical bone- bone area, total area, bone area 
fraction, bone mineral density, cortical thickness; distal epiphysis and femoral neck 
trabecular bone- bone volume, total volume, bone volume fraction bone mineral density, 
trabecular thickness, trabecular spacing, trabecular number, connective density, structure 
model index. Statistical significance, * p< 0.05, determined by one-way ANOVA with 
Tukey’s post-hoc test, n=4-6 mice per group. Abbreviations: PCA, principal component 
analysis; F.N., femoral neck; Ep., Epiphysis; M.D., mid diaphysis; Conn. Den., 




During human development, bones grow in length due to a process called 
endochondral ossification, where an avascular matrix of cartilage formed by 
chondrocytes in the physis of the bone is resorbed by osteoclasts and new bone is formed 
from the deposit of bone matrix by osteoblasts [130]. Once the physis is fully resorbed, 
epiphyseal fusion occurs, and the bone has reached skeletal maturity. This process is 
thought to be impaired and potentially occurs too quickly in sickle cell children [132, 
133]. Children with SCD often are of reduced stature or height, have abnormal lengths in 
their femurs resulting in a limp or altered gait, and even see bone abnormalities as early 
as 19 months [132, 133, 149].  
For the first time, we characterized epiphyseal plate fusion in a sickle transgenic 
mouse model. In a previous study, male C57BL6 mice had undergone epiphyseal fusion 
in the proximal femur by 4 months, while only approximately 60% of C57BL6 female 
mice had undergone epiphyseal fusion by 6 months [130]. This is opposite of what has 
been witnessed in clinical data in which females on average reach skeletal maturity by 
age 17 and males reach this milestone by age 18.5 [150]. In our study we saw fusion 
occur in AA and AS mice by 5 months, but not SS males (Figure 3.2A). During 
longitudinal bone growth, the growth plate is composed of three zones of resting, 
proliferating, and hypertrophic chondrocytes, with the latter two arranged in columns. 
Once the growth plate enters the senescence phase of development, the proliferating and 
resting chondrocytes become disorganized, and the zone of hypertrophy becomes 
diminished [130, 151].  At 5 months, SS males and all three genotypes in the females 
appear to be still in the senescence phase of development, indicated by the presence of 
disorganized chondrocytes that are not flanked by ossified bone (Figure 3.4A-B). The 
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lack of ossified bone is further apparent in our BV/TV measurements. BV/TV has been 
shown in previous studies through Archimedes’ principle to be directly proportional to 
bone mineral density [152].  We demonstrate that BV/TV in SS 5-month males is 
decreased in comparison to AA and AS (Figure 3.2B). By 12 months, we show that 
fusion does occur in the male mice with even an increased BV/TV in the proximal femur 
in comparison to SS males at 3 and 5 months (Figure 3.5A-B) We speculate to the reason 
why this delay in ossification occurs in the sickle environment. In order for fusion to 
occur in mice, chondrocytes in the physis differentiate and allow hypoxia inducible factor 
1 alpha (HIF1-)-induced production of vascular endothelial growth factor (VEGF) 
[153]. This allows for blood vessels to enter the epiphysis around 12 weeks, induction of 
chondrocyte apoptosis, resorption of the physis, and thus complete ossification of the 
epiphysis through the cartilage being substituted for trabecular bone by 15 weeks [130]. 
In mice this process is controlled through intricate timing between the expression of 
VEGF from chondrocytes from the physis (starting at 5 weeks) and the epiphysis 
(starting at 10 weeks) [130, 154]. We hypothesize that since the skeletal maturation in 
sickle mice is delayed, this production of VEGF is inhibited or delayed and thus so is the 
ossification of the epiphysis. Moreover, VEGF is upregulated in the growth plate of 
humans undergoing puberty, a stage of development that is delayed in children with SCD 
[155, 156]. Scantiness of other growth factors could also be playing a role in delayed 
epiphyseal fusion in SCD. Vitamin D in mammals leads to a decrease in chondrocyte 
proliferation and increase in hypertrophic chondrocyte apoptosis in the growth plate [157, 
158] . Consequentially, people with SCD who have suffered several bone injuries also are 
plagued with vitamin D deficiency [159]. Furthermore, chondrocytes in the physis are 
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adapted to proliferate and survive hypoxic environments [160]. If the vasculature that 
crosses into the epiphysis is blocked due to sickled RBC vaso-occlusions, then 
chondrocytes are allowed to remain in a prolonged hypertrophic state that delays the 
complete ossification of the epiphysis. In pediatric patients, the BMD is decreased in the 
proximal femur due to vascular occlusions [2]. Furthermore there is evidence that this 
type of epiphyseal fusion is impaired in sickle patients in the metacarpals, metatarsals, 
and phalanges; these long bones in sickle cell patients can undergo premature fusion of 
the epiphysis and thus result in short fingers [161]. Future studies are needed in which 
hypoxic conditioning of AA and AS male mice will be performed to see if a similar delay 
in epiphyseal fusion as we saw in the SS mice occurs. Also, characterization of the 
vascular development within the proximal femur of all three genotypes to ascertain if 
blood vessels cross into the epiphysis at the expected time point of 12 weeks is needed.   
SCD’s effect on delaying bone development is further evident in our correlation 
plots relating BV/TV of the proximal epiphysis to mouse body weight in 5-month mice. 
For SS males, there is no correlation, while we see a significant positive correlation for 
AA and AS males (Figure 3.5C). This shows that SCD hinders overall growth and 
skeletal development. These findings coincide with clinical data in which adolescent 
males with SCD were discovered to have lower mean body weight and body mass index 
in comparison to the non-sickle population [155]. AA females also have no correlation of 
their body weight to BV/TV, demonstrating that SCD causes for males, who are typically 
larger in size, to be on the same level of growth as females (Figure 3.5D).  Furthermore, 
SS females’ body weight is negatively correlated with BV/TV, demonstrating that as 
their body weight increases, the BV/TV actually decreases (Figure 3.5C-D). According to 
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Iwaniec et al., alterations to body weight come before any adjustments are made to the 
skeletal system that will allow bones to properly handle the modification in the 
mechanical loads [162]. Our data suggests that even though the sickle mice are growing, 
there is delayed development in the femurs. This postponed response puts sickle cell 
patients at an even greater risk for fracture, especially growing children [162] [163].  
Another aim of this study was to characterize the sickle bone phenotype over time 
in female and male mice in comparison with control and sickle-trait mice. Although bone 
mineral density measured with DXA is the standard clinical metric to evaluate overall 
bone health, we utilized microCT to measure BMD of cortical and trabecular bone in 
order to not muddle our results with metrics gleaned from any surrounding muscle or 
other soft tissue. Furthermore, microCT imaging is capable of detailed assessment of  
trabecular bone morphology [164].  In the femoral neck, there were no significant 
differences for trabecular BMD for male or female mice (Figure 3.6E).  However, the 
trabecular BMD in the distal epiphysis for 5-month-old SS females was reduced in 
comparison to AA and AS (Figure 3.7E). This finding is in accordance with a previous 
study in female sickle mice as well as in human studies that have found reduced BMD in 
adult and pediatric patients [42, 134, 142, 165]. However, consideration must be taken in 
that our results are looking at a specific region in the bone, while the aforementioned 
studies analyzed the entire femur. Similarly, to Green et al.’s findings, we did not see any 
reduction in BMD for male mice in comparison to their age matched controls [45] 
(Figure 3.7E). However, our data makes the novel finding that there are sex differences in 
how SCD effects the BMD of trabecular bone within the distal femur. Finally, within the 
mid diaphyseal region, BMD was decreased at 3 and 5 months for males and females in 
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comparison to AA and/or AS controls (Figure 3.8B). This is again accordance with a 
Xiao et. al who also saw this reduction in cortical BMD for female mice, but Green et. al 
did not find differences among their male subjects [45, 134]. This discrepancy could be 
due to the fact that we utilized AA transgenic Townes mice as our control rather than 
wild-type C57BL/6 mice as in the Green study [166].  
In order to further illustrate the microarchitecture of bone in male and female 
mice, we looked at additional structural parameters through microCT analysis and 
discovered further changes in SS bone in comparison to AS and SS that are sex 
dependent. Male and female SS mice have varying trabecular morphology in the 
proximal and distal end of the femur (Figure 3.6, Figure 3.7). In the proximal region or 
femoral neck, SS females have reduced Tb.Th.  at 5 months in comparison to age-
matched controls, which means there is loss of trabecular bone, whereas male SS animals 
see an increase in Tb.Th. from 3 to 5 months (Figure 3.6B). This suggest that older 
female sickle patients may be at greater risk for fracture at the femoral neck. However, 
for proximal trabecular bone in general, SCD does not decrease the strength of the bone 
which is apparent in no significant changes to the BMD (Figure 3.6B).  In the femoral 
neck, we surprisingly see more of changes with respect to age in male mice then with 
respect to genotype. BV/TV and Tb.Th. increase while SMI decreases with age (Figure 
3.6B-D). SMI is a parameter that measures the plate-to-rod like structure of the 
trabeculae [148]. With aging, trabeculae change their shape from more plate like, a SMI 
score of 0, to more rod-like, a SMI score of 3 [139]. Any scores in between these values 
are to indicate a structure with a mixture of plates and rods  [139]. However, we see in 
the male mice a decrease in SMI not necessarily due to magnitude but in positivity. A 
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negative SMI value means that surface of the bone is concave rather than the convex 
assumption that is made in the parameter measurement [167]. With this in mind, it 
appears male mice’s overall plate-rod ratio is not changing with time, but just the 
convexity. In the distal epiphysis, SS females also have weaker, less dense trabecular 
bone as is apparent by the reduction in BMD and Tb.Th. (Figure 3.7B, E). However, the 
trabecular bone that is present has more connections and less spaced apart in SS females 
in comparison to controls, which means SBD does affect the overall Tb.N. (Figure 3.7D). 
However, in SS males there is no decrease in Tb. Th. or BMD (Figure 3.7B, E). This 
suggests that sickle trait and SCD results in reduced trabecular bone growth with age only 
in female mice.  These differences in trabecular morphology being site and sex dependent 
coincide with clinical data in which cancellous bone loss seen with age in men and 
women does not happen uniformly at each section such as the iliac crest or vertebrae[168, 
169]. Overall, there is evidence of trabecular bone loss in SS females, but not in SS males 
indicating that the trabecular bone loss characteristic of SBD is sex dependent. 
In the mid diaphyseal region we found the Cort. Th. and BA to be reduced in male 
and female SS mice (Figure 3.8B, D). These findings are in accordance with previous 
studies that have characterized the cortical bone in male or female mice at similar ages 
[45, 134]. The Cort. Th. and BA being decreased in SS animals speaks to the bone not 
being able to withstand as high of mechanical loads in comparison to AA and AS bones. 
Reduced Cort. Th. and BA has been attributed to decreased mechanical strength of bone 
[147, 166]. This puts sickle bone at an increased risk of fracture. Furthermore, we have 
discovered differences in the cortical as well as the trabecular structure in male and 
female SS mice (Figure 3.6, Figure 3.7, Figure 3.8). Due to the fact that varying cortical 
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and trabecular architectures can have an effect on the mechanical properties of bone  
[170, 171], we aim to do mechanical testing in the future to ascertain if these differences 
have any effect on the biomechanical loadings that SS male and female femurs can 
withstand.  
From our microCT findings, we wanted to elucidate what mattered the most when 
characterizing bone loss in SCD: genotype, sex, or age. When plotting all of our groups 
together in the PC space (AA, AS, SS males and females at 3 and 5 months) we did not 
see any separation in the data (Figure 3.9A-B).  However, the data did cluster into distinct 
groups once we separated it by age (Figure 3.10, Figure 3.11). This demonstrates how 
important age is when studying bone development and the need for age-matched controls. 
At 3 and 5 months, SS males and females mostly separated from AA and AS males and 
females (Figure 3.10A, Figure 3.11A). This demonstrates that regardless of sex, sickle 
mice have distinct bone phenotype different from AA and AS mice. Additionally, we 
wanted to ascertain which of the 23 bone parameters we analyzed lead to the separation 
of sickle animals from non-sickle. Trabecular parameters of SMI and Conn. Den. are the 
most important factors in distinguishing the sickle bone phenotype (Figure 3.10, Figure 
3.11). This of great interest since trabecular bone architecture takes on 75% of external 
loads and thus is of great importance in bone resisting fracture [172]. Trabecular bone is 
known to change from plate-like (score of zero) to rod-like (score of three) architecture, 
which is indicative of trabecular thinning, due to the bone loss and imbalance in 
remodeling that occurs as people age [146, 164, 173]. When performing linear regression 
analysis of trabecular bone microCT parameters, SMI was the best predictor of elastic 
modulus of human bone [174]. As SMI increased, the elastic modulus decreased, 
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indicating rod-like trabecular architecture leads to weaker bones. This relationship is 
further evident in a large-animal model, where SMI was able to predict the ultimate 
strength of trabecular bone [175]. In our analysis, 3-month-old SS male mice had a 
significant increase in SMI in comparison to their age matched controls, indicating 
premature aging and thinning of the bone (Figure 3.10E). However, by five months, this 
difference in SS SMI is no longer present (Figure 3.11E). Conn. Den. which is 
normalized by total volume of bone, relays how many links there are between trabeculae 
that can be severed before the construct can be divided into two [148].  The relation to 
Conn. Den. and mechanical properties of bone are still up for debate. In the 
aforementioned previous two studies, Conn. Den. was a poor predictor of elastic modulus 
and strength [174, 175].  However, Kabel, et al. argues that Conn. Den. is limited in 
being able to ascertain bone elastic properties, but that it is a better predictor for 
mechanical strength in bone that has undergone pathologic remodeling, such as in SBD 
[176]. Alterations to connectivity has been suggested as the cause for the reduction in 
bone strength related to age [177]. One study found that connectivity loss during bone 
remodeling  is indicative of trabecular fracture and is, therefore, directly linked to a 
deficiency mechanical stiffness and strength [178]. Bone turnover rate and osteoclast 
activity have been shown to be increased in SS mice while bone formation has been 
shown to be decreased [134, 137]. With this increase in bone remodeling, this makes SS 
mice susceptible to loss in connectivity and thus decreased mechanical strength. In our 
analysis we actually see increased Conn. Den. in the distal epiphysis for 5-month females 
(Figure 3.11C), which should mean they have greater mechanical strength than AA or 
AS.  However, Tb. Th. has been correlated to mechanical strength of bone [179], and SS 
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females have decreased Tb. Th. as well at 5 months (Figure 3.7B). Collectively, this 
suggests that even though certain trabecular parameters lead to the most variance in the 
microCT data, one or two of them cannot give a complete picture of what is happening in 
the sickle trabecular morphology. This further implores us to perform mechanical testing 
in future studies. Our data, however, still drives home the fact that trabecular morphology 
is what distinguishes the sickle bone phenotype and should be studied extensively in a 
complete context utilizing multiple parameters.   
 In conclusion, we have shown in this work for the first time the novel 
characterization of SBD within both male and female mice. We found that SCD delays 
skeletal maturity in male mice. Essentially, this research demonstrates that the Townes 
sickle transgenic mouse model can be used to study growth retardation that plagues 
people with SCD. Additionally, we demonstrate that trabecular bone morphology 
changes in male mice with respect to age as opposed to with respect to genotype as in 
female mice. Consequentially, we found that trabecular parameters are what distinguishes 
the sickle bone phenotype from normal and sickle-trait controls. Thus, this study implores 
the need to study both sexes when studying SBD and to focus upon trabecular bone loss 
as future therapeutic targets, especially for female SS patients.   
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CHAPTER 4  Dysregulated Sphingolipid Metabolism Enhances 
Cathepsin Proteolytic Activity that Promotes Pathological Bone Loss 
in Sickle Cell Disease  
4.1 Introduction 
Sickle cell disease (SCD) is the most prevalent inherited blood disorder in the 
United States. Every year approximately 1 in 360 African Americans are born with this 
disease, while as many as 1 in 13 are born as genetic carriers [1, 180]. SCD is caused by a 
missense mutation in the -globin subunit of the hemoglobin gene that results in red 
blood cells (RBCs) or erythrocytes to bend into an abnormal “sickle” shape in states of 
hypoxia. This deformation of the RBC membrane causes RBCs to lose their flexibility 
and therefore the capability of being able to travel in small vessels such as capillaries. 
Additionally, sickled RBCs become more “sticky” and adhere to monocytes and the 
endothelium in vessel walls, forming cell aggregates that lead to blocked blood vessels 
[26]. This leads to painful complications known collectively as vaso-occlusive crises 
which can lead to tissue neurosis and eventual organ failure. Due to the intricate 
microvasculature present within bone, SCD also affects bone health.  
 A collection of pathologies, including osteonecrosis (ON), osteoporosis, and 
osteopenia, known as sickle bone disease (SBD), are among the most common 
complications of SCD and progresses from adolescence, occurring in 50% of individuals 
by age 35 [4, 45]. To prevent the progression of joint damage, bed rest and avoiding 
activities such as running or stair climbing are recommended, but these methods 
drastically affect the quality of patient life [7]. Surgical treatments, such as a total hip 
replacement (which can occur as early as age 18), have an elevated risk of inducing 
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complications such as acute chest syndrome, infection, and congestive heart failure for 
sickle cell patients [8, 9]. With these current inadequate treatment options, there is a great 
need to find targets for new therapies for SBD.    
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that has been 
implicated in many bone processes. S1P acts on cells’ extracellular membranes by 
signaling through 5 G-protein coupled receptors (S1PR1-5), as well as intracellularly to 
initiate a variety of cellular processes such as differentiation, migration, and apoptosis 
[58-61]. In the context of bone homeostasis, S1P has an active role in regulating new 
bone formation as well as resorption. In human mesenchymal stem cells (MSCs) and 
mouse myoblasts, S1P increased the differentiation of the cells into osteoblasts [181, 
182]. Osteoblasts are responsible for the synthesis of new bone, production of bone 
matrix proteins such as type 1 collagen, and subsequent mineralization of bone. Other 
studies have shown that this process is propagated through S1PR2, whose activation 
increases the expression of transcription factor RUNX2 that is needed for osteoblast 
differentiation [14]. Additionally, S1P, via its receptors S1PR1 and S1PR3, increases the 
migration of human MSCs in vitro [18]. S1P also directs the differentiation of 
osteoclasts, cells that resorb bone. By increasing the osteoblast production of receptor 
activator of nuclear factor -B ligand (RANKL), S1P has been shown to increase 
osteoclastogenesis [15]. This process is further amplified when cathepsin K (cat K), a 
cysteine protease used by osteoclast to resorb bone, is deleted in osteoclasts as a feedback 
mechanism to increase osteoclast differentiation [16]. S1PR1 and S1PR2 has also been 
shown to direct the migration of osteoclast progenitors (OPCs) in and out of the bone 
marrow (BM) niche [70]. Studies in sickle murine models have discovered that there is 
an unbalance in bone homeostasis that contributes to the bone loss in SBD. Increased 
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osteoclast activity and reduced MSC terminal differentiation into osteoblasts contributes 
to bone loss and impartment in SCD mice [134, 137]. With this information in mind we 
set out to further characterize the role of S1P in the BM niche of SCD. We hypothesized 
that SS MSCs dysregulated sphingolipid metabolism and increased osteoclast progenitors 
in SCD mice could contribute to the imbalanced bone formation and resorption in SCD.  
Previously, our work and others have shown that sphingolipid metabolism is 
dysregulated in SCD. We found that S1P, as well as its precursor sphingosine (So), are 
elevated in the blood, plasma, and in RBCs of human sickle donors. Additionally, we 
found an increase in sphingosine kinase 2 (SK2), one isoform of the enzyme that 
phosphorylates So to produce S1P [10]. Zhang et al. discovered that inhibiting SK1, 
another isoform of SK, leads to decreased RBC sickling and diminished tissue necrosis 
[12]. We also have shown an increase in acid sphingomyelinase (SMase) activity in 
sickle (SS) RBCs. Acid SMase alters the biconcave shape of RBCs and induces the 
production of lipid-raft-rich microparticles (MPs) [183]. We found that proinflammatory 
RBC-derived MP production is increased in SS human donors. Additionally, we 
discovered that these MPs when engulfed by monocytes, lead to an increase in the 
production of proinflammatory, osteoclastogenic cytokines IL-6 and TNF- [10, 184]. 
Additionally, MPs have been utilized as biomarkers for ON in sickle patients [11]. As 
stated earlier, osteoclasts utilize cat K to resorb bone. Keegan et al. has shown that cat K 
activation is increased in SCD and disrupts vascular integrity [17]. Carbonare et al. has 
also shown an increase in cat K expression in SS mice in sickle crisis [137]. With our 
knowledge of sphingolipid metabolism being dysregulated in SCD and the S1P link to cat 
K expression in osteoclasts, we sought out to investigate cathepsins’ potential role in 
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pathological bone remodeling in SBD. We hypothesized that there is a link between 
sphingolipids and cathepsins that can elucidate viable targets for SBD.  
In this study we demonstrate a mechanism for SBD of dysregulated sphingolipid 
metabolism and increased osteoclast cathepsin activity. Through lipidomics and flow 
cytometry, we infer that increased S1P in the blood contributes to the imbalance in bone 
formation and resorption in SCD. Furthermore, we utilize enzyme zymography to 
establish that SS MPs increase cathepsin activity of immune cells as well as SS 
osteoclasts have elevated cat K activity, which leads to increased bone degradation. 
Utilizing the cysteine cathepsin inhibitor E-64, we are able to demonstrate for the first 
time that cathepsins are a viable target to treat SBD. This work exhibits the novel 
mechanistic link between sphingolipid metabolism and cathepsin activation in SCD that 
contributes to the progression of SBD. 
4.2 Materials and Methods 
4.2.1 Animals 
Animal procedures and animal care protocols were performed in accordance and 
with approval from the Georgia Institute of Technology or the University of Virginia 
Animal Care and Use Committee. We utilized wild-type C57BL/6 and Berkley SCD Tg 
mice, solely expressing human sickle hemoglobin (HbS) [185], for blood lipidomic 
studies. Berkley and C57BL/6 mice underwent hypoxic conditioning for 24 hours in a 
polypropylene hypoxia chamber (Coy Laboratory Products) at 8% oxygen that was 
maintained with nitrogen gas. We used Townes transgenic sickle mice that were non-
carriers (AA), heterozygous (AS), or homozygous (SS) for the sickle mutation from 
Jackson Laboratories (C57BL/6 and 129 background) [143] for all other studies. The 
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genotype of the Townes mice was determined through Native polyacrylamide gel 
electrophoresis (PAGE) of their blood obtained via the tail vein. One-month old mice 
were injected with sterile saline or 9mg/kg of the drug E-64 via intraperitoneal (IP) 
injection daily for 2 months. Femurs from 3-month old male and female mice were 
isolated for microCT analysis, four-point bending mechanical testing, and histological 
analysis. The bones were stored at -20C until time of evaluation.    
4.2.2 MSC In Vitro Culture1 
MSCs from 4-6-week-old Townes mice of all three genotypes (AA, AS, SS) were 
isolated according to a previous protocol [186]. Briefly, bone marrow (BM) cells were 
flushed from murine long bones and collected in -MEM media supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 1% penicillin-streptomycin (Gibco), 2.2mg/ml 
sodium bicarbonate, and plated in a 100-mm petri dish. Five days later, the cells were 
passaged into a tissue culture flask at 1.5x106 cells/cm2 seeding density. The media was 
changed every 3-4 days and cells were passaged at 60-80% confluence. 
4.2.3 Whole Blood, RBC-Derived MPs, and MSC Lipidomic Analysis  
Whole blood for lipidomic analysis was harvested by cardiac puncture from 
Berkley and C57BL/6 mice immediately before and after hypoxic conditioning. RBCs 
                                                 
 
 
1 Adapted from: J.M. Selma, A. Das, A.O. Awojoodu, T. Wang, A.P. Kaushik, Q. Cui, H. Song, M.E. Ogle, 
C.E. Olingy, E.G. Pendleton, K.F. Tehrani, L.J. Mortensen, E.A. Botchwey, Novel Lipid Signaling 
Mediators for Mesenchymal Stem Cell Mobilization during Bone Repair, Cell Mol Bioeng 11(4) (2018) 
241-253. Reprinted with permission from Springer Nature  
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isolated from human AA and SS donors were isolated from whole blood through density 
fractioning with Ficoll-paque (GE Healthcare). RBC-derived MPs were isolated from the 
RBC fraction through ultracentrifugation. Passage 1 MSCs isolated from Townes AA, 
AS, and SS mice, RBCs from Berkley and C57BL/6 mice, and human AA and SS RBC 
MPs were used for sphingolipidomic analysis based on a previously published method 
[187]. Two classes of sphingolipids were quantified: sphingoid bases which include 
sphingosine, sphinganine, sphingosine-1-phosphate, and sphingaine-1-phosphate and 
complex sphingolipids which include sphingomyelins, ceramides, and glucosylceramides 
(Table 4.1). Different acyl chain lengths were measured for each complex sphingolipid 
(Table 4.1). Separate extraction methods were utilized to quantify long chain bases and 
complex sphingolipids. Sphingoid bases were separated using reverse phase liquid 
chromatography, and complex sphingolipids were separated using normal phase liquid 
chromatography. For absolute quantification, 25 pmol/sample of an internal standard 
(Avanti Polar Lipids) was added to each sample, and each sample was normalized to its 
total protein content determined via a BCA assay. Calibration curves were generated with 
the internal standard lipid cocktail at 0.5-1000 pmol per 50uL injection to allow 
quantitation. Sphingolipids were quantified through high-performance liquid 
chromatography-tandem mass spectrometry (HPLC-MS/MS) using a Micromass Quattro 
LC triple quadrupole tandem mass spectrometer (Waters).  
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4.2.4 Characterization of MSCs and OPCs  
BM was harvested from both femurs and tibias of Townes mice euthanized by 
CO2 inhalation. BM-derived cells were isolated in phosphate buffered saline (PBS) 
supplemented with 3% FBS to characterize MSCs and OPCs via FACS analysis. Flow 
cytometry immunophenotyping was performed according to standard procedures and was 
analyzed on a BD FACSAria II or Fusion cytometer. Fluorophore conjugated monoclonal 
antibodies to stem cell antigen-1 (Sca1), CD45, CD34, CD90, CD29, and CD44 were 
used to identify MSCs while antibodies for CD11b, CD3, CD45R/B220, CD117, and 
CD115 were used for OPCs as previously described [188]. Live cells were determined by 
utilizing the live/dead stain of Zombie Violet (Biolegend).  
4.2.5 Microparticle Isolation and THP-1/PBMC incubation  
 Primary RBCs and peripheral blood mono-nuclear cells (PBMCs) from human 
AA and SS donors were isolated from whole blood through density fractioning with 
Ficoll-paque (GE Healthcare). RBC-derived MPs were collected from the RBC fraction 
diluted 10-fold in PBS. The RBC-PBS solution underwent ultracentrifugation at 
37,000xg for 1 hour at 4ºC. The supernatant was removed, and MPs were resuspended in 
PBS for cellular treatment or lipidomic analysis. Contamination of RBCs was removed 
from the PBMC fraction using RBC lysis buffer (0.835 ammonium chloride, 0.1% 
potassium bicarbonate, and 0.0037% EDTA). THP-1cells, human monocytes, were 
cultured in RPMI-1640 medium (Sigma-Aldrich) augmented with 10% FBS, 1% 
penicillin-streptomycin, and 0.05 mM -mercaptoethanol.  THP-1 monocytes, AA 
PBMCs, and SS PBMCs (2 x 105 cells per/well) were treated with 1 x 106 SS MPs for 24 
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hours in a 24 well plate. After three washes with PBS, cells were isolated and prepped for 
enzyme zymography. 
4.2.6 Osteoclast Differentiation  
BM-derived cells isolated from Townes mice were collected in 24-well plates in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% heat-inactivated 
FBS, 1% L-glutamine, 1% sodium pyruvate (Gibco), 5% heat-inactivated horse serum, 
1% penicillin-streptomycin (Gibco), 1% MEM-essential amino acids (Gibco), 50uM  
−mercaptoethanol, and 10ng/mL of macrophage colony stimulating factor (M-CSF) for 
24 hours. After 1 day, the media was changed, and the control wells were supplemented 
with 10ng/mL M-CSF while the experimental wells were supplemented with 30ng/mL 
M-CSF and 100ng/mL RANKL. The media was changed every other day for 21 days. 
Osteoclast differentiation was verified via a tartrate-resistant acid phosphatase (TRAP) 
and nuclear staining kit (Takara Bio, Kusatsu Japan). 
4.2.7 THP-1/PBMC and Osteoclast Cathepsin Zymography  
 Protein from AA and SS osteoclast samples as well as THP-1/PBMC samples that 
were treated with MPs was collected in lysis buffer (20 nM Tris-HCl (pH 7.5), 5 mM 
EGTA, 150 mM NaCl, 20 mM β-glycerol-phosphate, 10 mM NaF, 1 mM sodium 
orthovanadate, 1% Triton X-100, 0.1% Tween-20) supplemented with 0.1 mM leupeptin 
and then resuspended in 5X reducing loading dye for zymography. For osteoclast 
samples, RAW 264.7 cells (mouse macrophages) were loaded along the samples to serve 
as a positive control. Enzyme zymography was completed utilizing a previously 
described protocol [189, 190]. Briefly, equal volumes of each sample were loaded into 
12.5% SDS-PAGE gels embedded with a 0.2% gelatin substrate at 4°C. To ensure that 
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cathepsins can bend into their active structures, gels were washed in renaturing buffer 
following electrophoresis. In order for the cathepsins to degrade the gelatin substrate, the 
gels were coated in sodium phosphate buffers (pH6) supplemented with 2mM 
dithiothreitol and 1mM EDTA for 18hrs at 37°C. Each gel was stained with Coomassie 
Blue, destained, and imaged with an ImageQuant LAS 4000 (GE Healthcare, Little 
Chalfont, UK). Proteolytic activity was visualized as white bands in the gels and 
quantified through densitometry by utilizing ImageJ. Specific cathepsins were 
distinguished by molecular weight. To further characterize proteolytic activity, gels were 
incubated with either 10μM E-64 or 1μM cat K inhibitor (1-(N-benzyloxycarbonyl-
leucyl)-5-(N-Boc-phenylalanyl- leucyl) carbohydrazide [Z-L-NHNHCONHNH-LF-Boc], 
EMD Biosciences) for 18hrs at 37°C. For MP gels, cathepsin bands were normalized to 
the non-MP-treated control groups run in each gel. For osteoclast gels, cathepsin bands 
were normalized to the maximum intensity for each gel. 
4.2.8 Cathepsin K Western Blot 
AA and SS osteoclast samples were resuspended in 5X reducing loading dye for 
SDS-PAGE and Western blotting. Human recombinant cat K was loaded along the 
samples to serve as a positive control. To ensure equal amounts of protein from each 
sample were loaded into the 12.5% polyacrylamide Western blot gels, a BCA assay was 
performed. Following separation of the samples by molecular weight, the protein from 
each gel was put onto nitrocellulose membranes. Cat K was detected by blocking 
membranes with Odyssey blocking buffer, staining the membranes with primary rabbit 
anti-mouse cat K polyclonal antibody (Proteintech Rosemont, IL) overnight, and finally 
staining with anti-rabbit secondary antibody (LI-COR, Lincoln, NE). The membranes 
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were imaged with a LI-COR Odyssey CLx (LI-COR, Lincoln, NE) machine.   
4.2.9 Histology  
Femurs were harvested, fixed in 10% neutral buffered formalin for 24 hours at 
4oC, and decalcified using a formic acid decalcifying solution (Immunocal, StatLab, 
McKinney Tx) for 3 hours at room temperature. The bones were embedded in paraffin 
and the 3-month-old distal ends were sectioned for and stained with TRAP and a 
hematoxylin counterstain. Bone sections were mounted with xylene mounting media 
(Thermo-Fisher) and visualized under a bright field microscope for positive staining.  
4.2.10 MicroCT Analysis  
Bone tissue mineral density (BMD) density and cortical and trabecular bone 
morphology within the femurs of 3-month and 5-month-old male and female mice were 
examined by microCT imaging (μCT 40, Scano Medical, SUI) as previously reported 
[45, 144]. The mid diaphysis (1mm region at femur mid-point, 66 slices), distal epiphysis 
(0.32 mm in length distal from the growth plate (or physis), 25 slices), and distal 
metaphysis (50 slices extending proximally towards the mid diaphysis from the starting 
point of 0.05mm above the growth plate) and were scanned at 12 µm isotropic voxel size. 
Each section of interest is depicted in Figure 3.1. The analysis settings were as follows: 
55kVp voltage, 144µA current, and a medium resolution (1024 X 1024-pixel image 
detection matrix). Cortical and trabecular bone were separated in each region utilizing an 
auto-contorting program, with additional manual adjustments for proper boundary 
allocation [145]. Mineralized and soft tissue were distinguished within the mid diaphysis, 
distal epiphysis, and distal metaphysis using a Gaussian noise filter of 0.8, support of 1, 
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and thresholding bone at 205-1000 mg hydroxyapatite (HA)/cm3, 162-1000 mg 
hydroxyapatite (HA)/cm3, and 155-1000 mg hydroxyapatite (HA)/cm3, respectively.  
Utilizing direct distance transformation algorithms in Scanco software [144, 146], 
we measured the cortical bone area (BA), total area (TA), cortical bone area fraction 
(BA/TA), and cortical thickness (Cort. Th.) for the mid diaphysis region. Additionally, 
the maximum moment of inertia around the medial-lateral axis (IMax) was measured for 
four-point bending analysis of the mid diaphysis region. For the trabecular bone in the 
distal epiphysis and distal metaphysis, we additionally measured trabecular spacing 
(Tb.Sp.), trabecular thickness (Tb.Th.), trabecular number (Tb.N.), trabecular 
connectivity density (Conn.Den.), bone volume (BV), total volume (TV), bone volume 
fraction (BV/TV), and structure model index (SMI). All scans were assessed by a blinded 
investigator.    
4.2.11 Mechanical Testing  
Utilizing force and deflection data gathered from a MTS 858 Mini Bionix system 
(Eden Prairie, MN), the mechanical properties of stiffness, ultimate stress, and maximum 
force were determined for femurs via four-point bending as previously reported [45, 144]. 
A load was administered to the mid diaphyseal region of freshly-thawed femurs at a rate 
of 0.04 mm/s until failure. The femurs were tested posterior-side up, with the mid 
diaphyseal region at approximately 3.1 mm between two support pins with a radius of 
curvature 0.5mm. The stiffness was determined as the slope of the linear potion of the 
force-deflection curve. The maximum moment of inertia about the medial-lateral axis, 
IMax was determined via microCT to calculate the ultimate stress.  
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4.2.12 Bone Marrow Transfer Studies  
Tibias and femurs were harvested from 2-month old AA and SS mice. The BM 
was collected by flushing the long bones with sterile saline by utilizing a 25-gauge needle 
and 10mL syringe. One week before bone marrow transfer (BMT), host mice were 
treated with 0.5 mg/ml Baytril (enrofloxacin) in their drinking water. Following lethal 
irradiation dose of 5 Gy with an X-ray irradiator (RS-2000), 2-month-old host C57/BL6 
and Cat K knockout (CatK-/-) mice received BM (~ 3 X 10^6 cells) from either AA or SS 
mice resuspended in 100µL of sterile saline through jugular vein injection. Following 
BMT, host mice were treated with 0.5 mg/ml Baytril in their drinking water for 7 days. 
Host mice were sacrificed at 6-months, 4 months post BMT, and microCT analysis was 
performed on the excised femurs.   
4.2.13 Data Analysis and Statistical Comparisons 
Principal component analysis (PCA) and volcano analysis was utilized on 89 
variables (sphingolipids) with MATLAB software (Natick, MA). Principal components 
(PC) were generated, with PC1 depicting the greatest percentage of data variance and 
PC2 (statistically independent from PC1) depicting the next utmost percentage of data 
variance. The MP data was prepared in a matrix with lipid species in rows and the 12 MP 
samples in the first column separated by genotype.  Linear regression analysis with 
confidence intervals as well as correlation coefficients between bone parameters and 
mechanical properties were produced with JMP (version 14).  
 Statistical comparisons were performed utilizing GraphPad Prism 8 (La Jolla, 
CA). The resulting analysis is conveyed as mean ± standard deviation (SD). Two-tailed t-
test was used for column analysis. For grouped analyses, one-way ANOVA with Tukey’s 
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post-test for multiple comparisons was utilized. For grouped analyses comparing data 
between control and E-64 treatment, two-way ANOVA with Tukey's multiple 
comparisons test was used. A p-value less than 0.05 was considered statistically 
significant.  
4.3 Results 
4.3.1 The sickle bone marrow niche is dysregulated  
 Due to our previous findings of increased So and S1P in the blood of sickle 
patients, we wanted to investigate if a similar dysregulation in sphingolipid metabolism 
was present in a sickle transgenic mouse model. In Berkley and wildtype mice, we 
implemented hypoxic conditioning for 24 hours to induce sickle crisis. We found So to 
be decreased after hypoxia in SS mice (0.32 ± 0.06 pmol/mg protein) in comparison to 
wild type (0.532 ± 0.04 pmol/mg protein) and SS (0.477 ± 0.17 pmol/mg protein) mice 
before hypoxia (Figure 4.1A). Conversely, we found S1P to be increased in the blood of 
SS mice before (2.32 ± 0.19 pmol/mg protein vs 2.86 ± 0.34 pmol/mg) and after hypoxia 
(2.89 ± 0.27 pmol/mg protein vs 3.408 ± 0.59 pmol/mg protein) in comparison to their 
timepoint-matched controls (Figure 4.1B). These results indicate that the phosphorylation 
of So to create S1P increases in sickle mice in hypoxic conditions. Since mouse sickle 
(SS) MSCs have previously shown lower osteogenic potential [134, 137] and that S1P 
and other sphingolipids play a role in bone development, we performed lipidomic 
analysis on MSCs from all three genotypes. MSCs were harvested from the BM and 
characterized through flow cytometry for known surface markers (CD29 (97.9%), CD90 
(98.2%), CD44 (98.1%), Sca1 (96.4%)) and for the absence of hematopoietic cell 
markers (CD45 (0.99%), CD34 (0.14%)) (Figure 4.1C). The long-chain-base 
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sphingolipid So was two orders of magnitude higher in SS MSCs in comparison to AA 
and AS (Figure 4.1D), while its phosphorylated successor, S1P, was not significantly 









Figure 4.1. Sphingolipid metabolism is dysregulated in the blood and bone marrow 
in SCD. Sphingolipid profile of blood from wild-type and SS mice before and after 
hypoxic conditioning including (A) sphingosine and (B) S1P (n= 6 mice per group). (C) 
Characterization via flow cytometry of MSCs isolated from Townes’ mouse model for 
MSC surface markers CD29, CD90, CD44, Sca1 and for the absence of hematopoietic 
cell markers CD45 and CD34. Unstained cells= gray, Single-stained cells=red. 
Sphingolipid profile of MSCs including the lipids (D) sphingosine and (E) S1P (n=3-5 
mice per group). Data expressed as mean ± SD. Statistical significance, * p< 0.05, 
determined by two way or one-way ANOVA with Tukey’s post-hoc test. Abbreviations: 




The other type of cell involved in bone homeostasis is osteoclasts, which can be produced 
from OPCs. OPCs circulate in the blood stream, migrate into the BM cavity, and 
eventually attach to the bone surface and mature into bone-resorbing osteoclasts [70]. 
Thus, we investigated whether there could be increased numbers of OPCs in the BM in 
SCD. Through flow cytometry gating for CD11b-, CD3-, CD45R/B220-, and 
CD117+/CD115+ cells (Figure 4.2A), we determined that the percentage of OPCs are 
increased in the BM of SS mice (0.11 0.05%) compared to AA mice (0.02  0.02%)  
(Figure 4.2B). This data gives an explanation as to why other studies have found 
increased osteoclast activity on the bone surface of sickle mice [137].  
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Figure 4.2. Bone marrow osteoclast progenitors are increased in SCD. (A) Flow 
cytometry identification of OPCs in the BM by gating for cells, live cells, CD11b-, 
CD45R/B220-, CD3-, and finally CD117+/CD115+ cells. (B) Quantification of OPC 
percentage of live cells in the BM of AA, AS, and SS mice (n=5-8 mice per group). Data 
expressed as mean ± SD. Statistical significance, * p< 0.05, determined by one-way 




4.3.2 Sickle RBC-derived MPs have a distinct sphingolipid profile  
 Previously, we have shown that So and S1P are increased in SS RBC-derived 
MPs [10]. With S1P’s vast role in bone homeostasis, we wanted to investigate if these 
sphingolipids solely aid in distinguishing SS MPs from non-sickle (AA) MPs. We 
performed HPLC-MS to quantify 89 complex and long-chain base sphingolipids. 
Through volcano analysis, we determined that four complex sphingolipids were 
significantly altered in SS MPs. Glucosylceramide (GlcCer) 22:0 (5.40 pmol/mg vs 18.90 
pmo1/mg) and GlcCer 24:0 (4.74 pmol/mg protein vs 25.64  pmol/mg protein) were 
significantly upregulated in SS MPs, while ceramide 1-phosphate (C1P) 18:2 (984.6 
pmol/mg protein vs 423.1 pmol/mg protein) and C1P 24:4 (52.94 pmol/mg protein vs 
62.76 pmol/protein) were significantly downregulated in SS MPs relative to AA MPs 
(Figure 4.3A). All of the aforementioned lipids’ expression except for C1P 24:4 were 
significantly altered in SS MPs relative to AA via t-test analysis (Figure 4.3B).  To 
further analyze our multivariate dataset, we utilized unsupervised principal component 
analysis (PCA) to determine exactly what sphingolipids contribute to the variability 
between AA and SS MPs. As depicted in Figure 4.3C, principal component 2 (PC2) 
separated our AA and SS MP datasets. Unsurprisingly, GlcCer 22:0 and 24:0 aided 
heavily in the separation, while C1P 18:2 and C1P 24:4 had the least effect on this 
separation. These lipids can be visualized in red in the PCA loadings graph in Figure 
4.3D. Furthermore, each ceramide (Cer) species, depicted in gray in Figure 4.3D, was 
found to be weighted heavily in the PC2 loadings, and thus distinguishes SS MPs from 
AA MPs (Figure 4.3D). In looking at each individual Cer species, we found Cer 16:0 
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(903.3 pmol/mg protein vs 2809 pmol/mg protein) and Cer 24:1(2656 pmol/mg protein 
vs 4689 pmol/mg) to be elevated in SS MPs (Figure 4.3E).   
 
 
Figure 4.3. SS RBC-derived MPs have a distinct sphingolipid profile and enhance 
cathepsin activity in monocytes. (A) Volcano plot analysis of 89 sphingolipids 
characterized for AA and SS MPs (n=6 donors per group). (B) Four lipids that were 
deemed significant between AA and SS MPs via volcano analysis (n=6 donors per 
group). (C) 2D scores plot of sphingolipids for AA and SS RBC-derived MPs. AA MPs= 
black, SS MPs= red (n=6 donors per group). (D) 2D loadings (weight coefficients) plot of 
the 89 input variables (sphingolipids) in the reduced principal component space.  Lipids 
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deemed significant via volcano analysis are depicted in red. Ceramides are depicted in 
gray (n=6 donors per group). (E) Fatty acyl chain lengths of ceramide sphingolipid class. 
Each acyl chain was deemed to add to the variance that separates AA and SS MPs by 
PCA (n=6 donors per group). (F) Representative cathepsin zymography gel of THP-1 
cells and AA and SS human PBMCs treated with AA and SS RBC-derived MPs. (G) 
Fold change of cat K and S activity relative to untreated cells in THP-1 cells and AA and 
SS human PBMCs treated with SS RBC MPs. Data expressed as mean ± SD. Statistical 
significance, * p< 0.05, determined by two-way ANOVA. Abbreviations: MP, 
microparticle; GlcCer, glucosylceramide; Cer, ceramide; DCer, dihydroceramide; SM; 
sphingomyelin, LSM, lysosphingomyelin; C1P, ceramide 1-phosphate; Sa, sphinganine; 
SaP, sphinganine 1-phosphate; PCA, principal component analysis; PBMC, peripheral 
blood mononuclear cells; Cat, cathepsin. 
 
4.3.3 Cathepsin activity is increased in SCD 
 In our previous work, we saw an increase in inflammatory, osteoclastogenic 
cytokine production in monocytes incubated with SS MPs [10]. We therefore became 
interested in the effect that SS MPs have on the activity of cat K and S, both of which 
have been implicated in bone remodeling [99].  When we incubated human monocytes 
(THP-1 cells), AA peripheral blood mononuclear cells (PBMCs), and SS PBMCs with SS 
MPs, we saw an increase in cat K and S activity via enzyme zymography (Figure 4.3F-
G). In this technique, protein substrates are loaded into and run through a gel. After 
electrophoresis, cathepsins can be identified based on the molecular weight and the 
appearance of white bands is indicative of protease activity as the gelation substrate is 
removed. When we calculated the fold change in cathepsin activity for each cell type 
treated with SS MPs relative to their corresponding controls, we found that cathepsin S 
activity was increased 115 and 8-fold in SS MP-treated AA and SS PBMCs, respectively 
(Figure 4.3G). Cat K activity was increased approximately 1.3-fold in SS MP-treated AA 
and SS PBMCs (Figure 4.3G). 
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With an increase in cat K activity in white blood cells up taking SS MPs and the 
increase in OPCs within SS BM, we then wanted to investigate if cultured SS BM cells 
would lead to an increase in osteoclast differentiation in vitro. Interestingly, mostly 
multinucleated osteoclasts formed from AA BM cells, whereas mature, activated 
osteoclasts (indicated by the presence of ruffled border) formed from SS cells (Figure 
4.4A-D). Similar to the OPC findings, there was a 64% increase in the number of 
osteoclasts (TRAP+, 3 nuclei) per well that developed from SS BM cells relative to AA 
BM cells (Figure 4.4E). We further characterized these cultured AA and SS osteoclasts 
cathepsin activity through zymography. As depicted in Figure 4.4F, cat K activity was 
apparent at the expected 75 kDa. We were also able to visualize other cathepsin activity 
at higher and lower molecular weights. As determined by quantification through 
densitometry, SS BM-derived osteoclasts had 267% and 180% more cathepsin activity at 
175kDa and 150kDa, respectively, compared to AA BM- derived osteoclasts (Figure 
4.4G). Additionally, we performed Western blot analysis to determine the expression of 
cat K in AA and SS osteoclasts. The expression for each identified molecular weight of 
cathepsin K, including mature cathepsin K at 37kDa, was also quantified by densitometry 
(Figure 4.4I).  Depicted in Figure 4.4H, SS BM-derived osteoclasts have up to 72% more 
cat K expression at higher molecular weights of 95kDa and 80kDa compared to AA BM-
derived osteoclasts. To further clarify the source of protease activity, we performed 
zymography on AA and SS osteoclasts in the presence of a broad cathepsin inhibitor E-
64. With E-64 incubation, protease activity is completely inhibited, demonstrating that 
the enzyme activity we see in Figure 4.4F is indeed from cysteine cathepsins (Figure 
4.5A). Furthermore, incubation with a cat K inhibitor showed diminished cathepsin 
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activity from osteoclast samples (Figure 4.5B). Through densitometry, we see that 
activity at 175kDa is completely inhibited for both AA and SS, but only completely 
inhibited at 150kDa for AA osteoclasts (Figure 4.5C). When comparing the ratio between 
cathepsin activity at each molecular weight between control and incubation with cat k 
inhibitor, we see no difference among AA and SS osteoclasts (Figure 4.5D). With this 
information, we sectioned distal femurs from all three genotypes to look at the osteoclast 
activity within the bone by staining for the presence of an enzyme secreted by osteoclast, 
tartrate-resistant acid phosphatase (TRAP). SS bone had an increase in the TRAP staining 
in comparison to AA and AS (Figure 4.4J-L). Collectively, this data suggests that SS 
osteoclasts are more active and produce more cat K than AA osteoclasts and thus 






Figure 4.4. Osteoclast differentiation and cathepsin activity is increased in SCD. 
Representative images of BM cells from (A, C) AA and (B, D) SS mice treated with 10 
ng/mL M-CSF (A-B) or 30ng/mL M-CSF + 100ng.mL RANKL (C-D) for 21 days. 
Osteoclasts are determined as TRAP positive (pink) and at least three nuclei (blue). (E) 
Quantified number of osteoclasts per well, (n=4 mice and 8 wells per group). (F) 
Representative cathepsin zymography gel of AA and SS osteoclasts (30ng/mL M-CSF + 
100ng/mL RANKL treated). Active protein appears as white bands.  Mouse RAW 
macrophages were used as a positive control. (G) Densitometry quantification of 175kDa, 
150kDa, 75kDa, and 50kDa bands of active cathepsin bands in AA and SS osteoclasts, 
(n=4 mice per group). (H) Representative western of cat K protein in AA and SS 
osteoclasts. Recombinant cat K was used as a positive control. (I) Densitometry 
quantification of 95kDa, 80kDa, 50kDa, and 37kDa (mature cathepsin K) bands of cat K 
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protein expression in AA and SS osteoclasts, (n=4-5 mice per group). AA=black and 
SS=red. Histological sections of distal femur (J) AA (K) AS and (L) SS bone stained 
with TRAP (pink) and counterstained with hematoxylin (purple). 10X images (top) scale 
bar 100 μm, 40X images (bottom) scale bar 20 μm.   Data expressed as mean ± SD. 
Statistical significance, * p< 0.05, determined by Welch’s t-test. Abbreviations: BM, 






Figure 4.5. Protease activity in bone marrow osteoclasts is executed by cysteine 
cathepsins, specifically cathepsin K. Representative cathepsin zymography gel of AA 
and SS osteoclasts (30ng/mL M-CSF + 100ng.mL RANKL treated) incubated with (A) 
broad cysteine cathepsin inhibitor E-64 or (B) cat K inhibitor. Active protein appears as 
white bands.  Mouse RAW macrophages were used as a positive control. (C) 
Densitometry quantification of 175kDa, 150kDa, 75kDa, and 50kDa of active cathepsin 
bands in cathepsin zymography gel treated with cathepsin K inhibitor. (D) Densitometry 
quantification of ratio of cathepsin zymography gel treated with vehicle or cat k inhibitor 
of 175kDa, 150kDa, 75kDa, and 50kDa active cathepsin bands (n=4-5 mice per group). 




4.3.4 E64 treatment increases cortical bone in SCD mice 
Due to previous studies demonstrating reduced cortical bone in SS femurs, we 
performed microCT analysis in the mid diaphyseal region to elucidate if E-64 treatment 
had any effect in reducing bone loss. In order to qualitatively analyze the 3D renderings 
of the mid diaphyseal region from AA, sickle-trait (AS), SS femurs and their 
corresponding treatment groups, we utilized 5 blind observers to rank the images based 
on Cort. Th. Unsurprisingly, SS femora ranked lowest in comparison to AA and AS; 
however, E64-treated SS bones ranked higher than SS bones (Figure 4.64A-B). These 
observations were further verified with the quantification through microCT of Cort. Th. 
being reduced in SS bone up to 25% in comparison to AA and AS (Figure 4.6C). 
However, E-64 treatment significantly increased Cort. Th. in SS mice by 9% (Figure 
4.6D). Similarly, there was up to a 22%, 36%, and 4% significant decrease in bone area 
(BA) (Figure 4.6E), bone area fraction (BA/TA) (Figure 4.6G), and bone tissue mineral 
density (BMD) (Figure 4.6I), respectively in SS in comparison to AA and AS. E-64 
treatment significantly increased BA and BA/TA by 10% (Figure 4.6F, H, J). This data 
demonstrates that E64 treatment is able attenuate the cortical bone loss that is 




Figure 4.6. E-64 treatment increases cortical bone in SCD mice. A) Representative 
3D heat maps of the mid diaphyseal region in AA, AS, and SS 3-month-old mice 
administered saline (top) or E-64 (bottom). A pseudocolor scale of blue (0 mm) to red 
(0.2mm) depicts cortical thickness. (B) Ranking of cortical thickness depicted in 3D 
images generated for 30 mice on a scale ranging from least thick (1) to most thick (30) by 
5 blinded observers. (C-J) Cortical bone parameters generated by microCT scans for mice 
treated with E-64 weekly from 1 month to 3 months of age including (C-D) cortical 
thickness, (E-F) bone tissue mineral density, (G-H) bone area fraction, (I-J) bone mineral 
density. (C, E, G, I) Comparison between AA, AS, and SS control via one-way ANOVA 
with Tukey’s post hoc test (n=7-9 mice per group). AA=black, AS= gray, SS= red. (D, F, 
H, J) SS mice solely compared to SS mice treated with E-64 via t-test. SS=black, SS with 
E-64=red (n=8-9 mice per group). SS Data expressed as mean ± SD. Statistical 
significance, * p< 0.05, scale bar 100 μm. Abbreviations: Cort. Th., cortical thickness; 




4.3.5 E-64 treatment increases trabecular bone in SCD mice 
We performed further microCT analysis on the distal end of the femurs to look at 
the effect of E-64 treatment on trabecular bone. In the distal epiphysis, qualitative 
analysis of the region of interest for AA, AS, SS and their corresponding treatment 
groups was performed also by 5 blind observers, ranking based on trabecular thickness 
(Tb.Th). The rankings were quite varied for this region. Surprisingly, AS and SS 
appeared to rank higher than AA, with a slight increase in rank for both genotypes with 
E-64 (Figure 4.7A-B). These observations were first contradicted by microCT in that the 
Tb.Th. was decreased up to 15% in SS femurs in comparison to AA and AS (Figure 
4.7C). However, part of our qualitive observations were verified in that E-64 significantly 
increased SS Tb.Th.  by 8% in comparison to untreated SS (Figure 4.7D). Additionally, 
the trabecular BMD for SS femurs was significantly decreased by 5% in comparison to 
controls; this parameter was enhanced by 5% with E-64 treatment (Figure 4.7E-F). In the 
distal metaphysis, however, we saw no difference among the three genotypes for the 
same bone parameters (Figure 4.8C, E). Furthermore, E-64 had no effect on sickle bones 
(Figure 4.8D, F). In our qualitative analysis, however, there was at least a visual effect on 
the bone due to the treated groups being ranked higher than the control samples in all 
three genotypes (Figure 4.8 6B).  This data demonstrates that E64 treatment is able to 
increase the trabecular bone in certain regions in sickle bone.   
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Figure 4.7. E-64 treatment increases epiphyseal trabecular thickness and bone tissue 
mineral density in the distal femur of SCD mice. (A) Representative 3D heat maps of 
the epiphysis region in AA, AS, and SS 3-month-old mice administered saline (top) or 
E64 (bottom). A pseudocolor scale of blue (0 mm) to red (0.09mm) depicts trabecular 
thickness. (B) Ranking of trabecular bone thickness depicted in 3D images generated for 
30 mice on a scale ranging from least thick (1) to most thick (30) by 5 blinded observers. 
(C-F) Trabecular bone parameters generated by microCT scans of the epiphysis for mice 
treated with E64 weekly from 1 month to 3 months of age including (C-D) trabecular 
thickness and (E-F) bone tissue mineral density. (C, E) Comparison between AA, AS, 
and SS control mice by one-way ANOVA with Tukey’s post-hoc test. AA=black, AS= 
gray, SS= red (n=7-9 mice per group). (D, F) SS mice solely compared to SS mice treated 
with E64 via t-test.  SS=black, SS with E-64=red (n=8-9 mice per group). Data expressed 
as mean ± SD. Statistical significance, * p< 0.05, scale bar 100 μm. Abbreviations: Tb. 




Figure 4.8. E-64 treatment does not impact metaphyseal trabecular bone structure 
in distal femur of SCD mice. (A)Representative 3D heat maps of the metaphyseal 
region in AA, AS, and SS 3-month-old mice administered saline (top) or E64 (bottom). A 
pseudocolor scale of blue (0 mm) to red (0.09mm) depicts trabecular thickness. (B) 
Ranking of trabecular bone thickness depicted in 3D images generated for 30 mice on a 
scale ranging from least thick (1) to most thick (30) by 5 blinded observers. (C-F) 
Trabecular bone parameters generated by microCT scans of metaphysis for mice treated 
with E-64 weekly from 1 month to 3 months of age including (C-D) trabecular thickness 
and (E-F) bone mineral density. (C, E) Comparison between AA, AS, and SS control 
mice by one-way ANOVA with Tukey’s post-hoc test. AA=black, AS= gray, SS= red 
(n=7-9 mice per group). (D, F) SS mice solely compared to SS mice treated with E-64 via 
t-test. SS= black, SS with E-64= red (n=8-9 mice per group). Data expressed as mean ± 
SD. Statistical significance, * p< 0.05, scale bar 100 μm. Abbreviations: Tb. Th., 




4.3.6 E-64 treatment improves mechanical properties of sickle bone 
To investigate the effect that E-64 treatment has on the mechanical properties of 
bone, four-point bending was performed on the murine femurs. Without treatment, SS 
bones were significantly less stiff than AA bones (Figure 4.9A). SS femurs were only 
capable of tolerating 46% less force and 37% less stress than AA femurs (Figure 4.9B-C). 
In comparison to AS bones, SS femurs could only withstand approximately 37% less 
force and 30% less stress (Figure 4.9B-C). The beneficial effect of E-64 is apparent in 
looking at the correlations between Cort. Th. and BA/TA, two parameters that are 
enhanced with E-64 in SS bones (Figure 4.6D, H), and the three aforementioned 
mechanical properties. In normal or AA bones, stiffness, maximum force, and ultimate 
stress are all positively correlated to Cort. Th. as well as BA/TA (Figure 4.9D-I). All of 
these correlations are negative (indicated by the negative slope of the fitted lines) for SS 
femurs (Figure 4.9D-I), which speaks to an altered physiological state of the bones. 
However, E-64 treatment of SS bones induces positive correlations for all 6 comparisons, 
making SS femurs more comparable to AA (Figure 4.9D-I). This effect is most 
substantial in the ultimate stress property where E-64 treatment induces a significantly 
positive correlation between ultimate stress and Cort. Th. (r=0.9489, p=0.013) as well as 
between the ultimate stress and bone area fraction (r=0.897, p=0.0496) (Figure 4.9F, I). 
This data shows that E-64 treatment improves the pathological state of the mechanical 
properties of sickle bone.  
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 Figure 4.9. E-64 treatment enhances mechanical properties of SS bones. Mechanical 
properties for 3-month femurs including (A) stiffness, (B) max force, and (C) ultimate 
stress. AA=black, AS= gray, SS= red. Correlation plots for SS, SS +E64, and AA 
animals between (D) cortical thickness and stiffness (E) cortical thickness and maximum 
force (F) cortical thickness and ultimate stress (G) bone area fraction and stiffness (H) 
bone area fraction and max force (I) bone area fraction and ultimate stress. AA=gray, 
SS= black, SS with E-64= red.  Data expressed as mean ± SD. Statistical significance, * 
p< 0.05, determined by two-way ANOVA with Tukey’s post-hoc test or correlation, n=5-




4.3.7 Stromal cat K does not contribute to SBD 
Cat K can not only be secreted by osteoclasts, but also by endothelial cells. Due to 
interaction with activated PBMCs, endothelial cells in sickle vessels have upregulated cat 
K activity [17]. We wanted to investigate then if the cat K secretion by stromal cells 
could be further enhancing the increased bone resorption present in SCD. To study this, 
we performed BMT studies in which wild-type C57BL6 mice and mice with a genetic 
knock-out for cat K (CatK -/-) received BM from AA or SS mice following lethal 
irradiation (Figure 4.10A) at 2 months of age.  In the mid diaphyseal region, C57BL/6 
mice that were given SS BM had Cort. Th. that decreased by 5% in comparison to 
C57BL/6 given AA BM (Figure 4.10C). Cort. Th. was also reduced by 12% in CatK-/- 
mice that received SS BM in comparison to mice that were reconstituted with AA BM 
(Figure 4.10C). In the distal epiphyseal region, C57BL/6 mice that were given SS BM 
had 35% less mineralized tissue or BV/TV in comparison to wild-type mice given AA 
BM (Figure 4.10E). Again, we saw a similar pattern for CatK-/- mice given SS BM, with 
a 26% reduction in BV/TV in comparisons to CatK-/- mice reconstituted with AA BM 
(Figure 4.10E). Collectively, this data suggests that active cat K in the hematopoietic 
cells leads to the bone loss that is present in SCD and not cathepsins that are active within 
stromal cells.   
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Figure 4.10. Cathepsin K inhibition in stromal cells does not increase SS bone. (A) 
Schematic and timeline of bone marrow transfer studies. (B) Representative 3D heat 
maps of cortical thickness in the mid diaphyseal region in C57BL/6 (top) and CatK -/-
(bottom) that received AA or SS bone marrow. A pseudocolor scale of blue (0 mm) to 
red (0.2mm) depicts cortical thickness. (C) Cortical thickness in the mid diaphyseal 
region generated by microCT. (D) Representative 3D heat maps of trabecular 
morphology in the epiphysis region of the distal femur in C57BL/6 (top) and CatK -/- 
(bottom) that received AA or SS bone marrow. A pseudocolor scale of blue (0 mm) to 
red (0.09 mm) depicts trabecular thickness. (E)Trabecular bone volume fraction in the 
epiphyseal region generated by microCT. AA bone marrow= black, SS bone marrow = 
red. Data expressed as mean ± SD. Statistical significance, * p< 0.05, determined by 
multiple t-tests with Holm-Sidak’s post-hoc test, n=3-7 mice per group, scale bar 100 μm. 






 In this work we have shown that sphingolipid metabolism and increased cathepsin 
activity in SCD are linked and serve as novel targets to combat SBD. Through 
lipidomics, we demonstrated that sphingolipid metabolism is dysregulated in the blood of 
a sickle mouse model. We demonstrate that this change in the blood also affects the BM 
niche in leading to the dysregulation of sphingolipids in MSCs, as well as increased 
OPCs in the BM of sickle mice. We see the further effect of sphingolipids in that SS MPs 
have a distinct sphingolipid profile, due to differences in glucosylceramide and ceramide 
species, that differentiates them from AA MPs. Furthermore, we demonstrate 
functionality differences in the MPs via SS MPs increasing the cathepsin activity of SS 
and to even a greater extent AA PBMCs. We see further increased cat K activity in 
cultured SS osteoclasts as well as increased osteoclast differentiation in SCD. With these 
findings, we implored a cysteine cathepsin inhibitor, E-64; this treatment increased the 
cortical and trabecular bone as well improved the mechanical strength of sickle femurs. 
Finally, through BMT studies, we demonstrated that this elevation in cathepsin activity 
contributes to the bone loss in SCD and is indeed due to cells of the hematopoietic 
lineage and not stromal cells.  
 We found that sphingolipid metabolism is dysregulated in sickle mouse model. 
Similarly, to the findings of Zhang et al. [12], we saw an increase in S1P before hypoxia 
in SS mice in comparison to wild-type (Figure 4.1B). This coincides with our and others’ 
findings that S1P is increased in the blood, RBCs, and plasma of sickle human donors 
[10, 191]. We also found an increase in S1P in SS blood after hypoxic conditioning in 
comparison to control. The S1P levels did increase in SS with hypoxic conditioning, 
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although not significantly (Figure 4.1B). The precursor to S1P, sphingosine (So), 
decreased in SS mice with hypoxia (Figure 4.1A). It has been established that there is an 
increase in sphingosine kinase 1 (SK1) activity in SS human and murine erythrocytes 
[12]. SK1 phosphorylates So in order to produce S1P. These observations suggest that in 
states of hypoxia or sickle crisis, So is extensively converted into S1P. This further 
corroborates early findings in which we saw an increase acid SMase activity under 
normoxic and hypoxic conditions in SS mice [10]. Acid SMase acts upstream of So on 
the sphingolipid SM to produce Cer, which is then converted into So by the enzyme 
ceramidase [46] . We have shown earlier that an increase in acid SMase activity increases 
under hypoxia, demonstrating that the sickling of erythrocytes happens before the 
increased activation of acid SMase [10]. Furthermore, one study showed an increase in 
SMase activity due to extensive RBC membrane bending [56]. However, Zhang et al. 
argues that SK1 and S1P actually increase the sickling of RBCs and that inhibition of 
SK1 leads to an increase in the RBC lifespan, thus reducing the enlarged spleen 
characteristic of SCD [12]. These combined findings suggest that sickling of erythrocytes 
in hypoxia increases acid SMase activity that further increases SK1 activation. The 
membrane changes that occur with the increased conversion of So to S1P further 
enhances sickling of RBCs. These conclusions are further substantiated by Sun et al.’s 
findings that increased RBC S1P in SCD binds to deoxygenated sickle hemoglobin (HbS) 
and further enhances HbS polymerization and therefore erythrocyte sickling as well 
[192]. Our current findings show that the sickling of erythrocytes further propagates the 
dysregulation of sphingolipid metabolism in SCD. 
 87 
 The dysregulation of sphingolipid metabolism in the blood has an effect on the 
BM microenvironment in SCD. We found that sphingolipid metabolism is dysregulated 
in sickle MSCs (Figure 4.1C-D). In the past, bone and blood formation have been thought 
to be mutually exclusive processes. However, there has been shown ample 
communication between stromal and hemopoietic cells, with osteoblasts and MSCs 
controlling hematopoiesis. Additionally, the two aforementioned cell types’ 
communication is enhanced through cell adhesion molecules [193]. We hypothesize that 
this close relationship between bone and blood cells thus results in SS MSCs’ function 
being compromised by the sphingolipid changes in the blood due to RBC sickling. Pradas 
et al. argues that lipid profiles are tissue-specific, but that lipids must remain adaptive in 
order to change biological properties and functions of cells based on their environmental 
cues [194]. For example, during chondrocyte differentiation, MSCs change their lipid 
profile, with sphingomyelins being expressed mostly during day 2 and 14, and S1P 
expression peaking on day 14 due to increased SK1 activity [195]. Interestingly, MSCs 
isolated from sickle mice have demonstrated diminished osteogenic potential in 
comparison to AA MSCs [134, 137]. Further study is needed in order to elucidate if our 
observed changes in the sphingolipid profile of SS MSCs impacts their osteogenic 
differentiation. Additionally, our data displays an increased number of OPCs in the BM 
of SS mice (Figure 4.2B). We hypothesize that the increase of S1P blood in SCD is the 
cause for this. S1P controls the migration of OPCs from the BM and the blood. OPCs 
possess the receptors S1PR1 and S1PR2. S1PR1 leads OPCs toward increased S1P in the 
blood. S1PR2 however initiates negative chemotaxis of OPCs away from high levels of 
S1P toward the BM [70]. Once in the BM, OPCs can attach to the bone and differentiate 
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into mature osteoclasts to resorb bone. In an area where there is minimal S1P, such as the 
BM, OPCs restore their S1PR1 expression to their outer membrane in order to migrate 
back into the blood by the S1P gradient [62]. In the blood, where S1P expression is 
significant, S1PR1is activated on OPCs and then quickly internalized to allow S1PR2 to 
dominate [62]. We hypothesize that due to the increased level of S1P in SCD, S1PR1 is 
overly internalized in OPCs, therefore causing for their increased chemotaxis to the BM 
where they can then lead to the increased bone resorption seen in SCD. For example, 
Ishii et al. found that S1PR2 knock out in mice led to osteopetrosis, suggesting that 
inhibition of S1PR2 causes a decrease in OPCs that are allowed to attach the bone surface  
[70]. Further studies should investigate the S1PR1 and S1PR2 expression on SS OPCs as 
well as intravital imaging to track the migration OPCs from the BM into the blood over 
time. Overall, our studies show that dysregulation in sphingolipid metabolism in SCD 
leads to changes in the BM microenvironment.  
We further discovered that SS MPs also have a different sphingolipid profile in 
comparison AA MPs that possibly contributes to differences in their functionality. When 
we performed PCA on all 89 sphingolipids that we characterized with HPLC-MS, we 
found that complex sphingolipids, GlcCers and Cers, separated MPs based on genotype 
along PC2 (Figure 4.3C-D). Complex sphingolipids contain a constant sphingoid 
backbone as well as a variable side fatty acyl chain that varies in the number of carbons, 
which usually range from 13 to 26, and double bonds.  Among the complex 
sphingolipids, small differences in acyl chain length or unsaturation can be functionally 
consequential; for example, the production of different Cer species in cell membranes 
impacts membrane morphology and fluidity [49, 50].  We found GlcCer 22:0 and 24:0 to 
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be increased in SS MPs (Figure 4.3A-B). GlcCers and other Cer derivatives promote 
osteoclastogenesis by increasing RANK production in osteoclasts [196, 197]. RANK 
production has in fact been found to be increased in SCD [134, 137]. Furthermore, Cer 
has been shown to induce apoptosis in several cell types, including osteoblasts and their 
precursors [198, 199]. RUNX2 and osteonectin, osteogenic markers, were found to be 
downregulated in SCD [137]. For the individual acyl chains, we found C16 and C24:1 are 
increased in SS MPs (Figure 4.3E). Interestingly, C16 and C24 ceramide fabrication 
ensues neutrophil and hepatocyte apoptosis [200, 201]. Our current findings regarding the 
sphingolipid profile of SS MPs gives some insight into how the sickle environment could 
lead to increased osteoclastogenesis and reduced osteoblast differentiation that has been 
characterized in sickle mouse models [134, 137]. 
Inflammation contributes to bone remodeling, and SCD induces chronic 
inflammation due to frequent sickling of RBCs and endothelial interactions that may 
prolong osteoclast activity [202]. The result is an abnormally high concentration of 
inflammatory proteins circulating in plasma of non-sickle individuals [203], with TNF-α 
and IL-6 being important ones. We previously found that SS MPs increase the production 
of the inflammatory cytokines TNF- and IL-6 in monocytes and macrophages [10]. 
TNF- and IL-6 are osteoclastogenic cytokines [204-207] and the latter has been 
implicated in increasing the expression of RANKL to attenuate osteoclast apoptosis in 
sickle patients as well to be increased in SS mice [137, 208]. Additionally, TNF- incites 
the expression of the cat K gene (CTSK) in osteoclast precursors and has increased cat K 
activity in endothelial cells in SCD [17, 209]. Cat K is a potent collagenase released by 
osteoclasts to degrade bone matrix in both mice and humans [210]. Cat S is mainly 
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present in antigen presenting immune cells and cleaves collagen as well as other 
extracellular matrix (ECM) proteins like laminin, fibronectin, and osteocalcin (a bone 
protein produced by osteoblasts). Consequentially, inhibition of cat S has been shown to 
increase osteoblastic differentiation as well as bone turn over [211]. Disruption of these 
proteins can impair bone formation and contribute to the unbalance between bone 
formation and bone resorption. Both cathepsins are expressed in osteoclasts during bone 
development in mice [212] as well as have been implicated in several orthopedic-related 
diseases such as osteoporosis and osteoarthritis [99]. We found that SS MPs increased the 
cat K and S activity in SS and AA PBMCs in comparison to untreated cells (Figure 4.3F-
G). This data suggest that monocytes and macrophages may play a role bone resorption 
in SCD due to the uptake of SS MPs. Blair et al. discovered that macrophages are able to 
absorb bone in acidic environment [213] . It has previously been shown that monocytes 
and macrophages are involved in bone resorption or display increased osteoclastogenesis 
in other chronic inflammatory diseases such as rheumatoid arthritis or osteoarthritis [214, 
215]. Furthermore, Zhao et al. discovered that increased S1P in SCD led to an increase in 
the production of the osteoclastogenic cytokine IL-6 in macrophages and subsequent 
tissue damage [57]. We hypothesize that difference in the sphingolipid profile in SS MPs 
contribute to the increase in inflammatory response of immune cells and thus increased 
cathepsin activation as well. Future studies are needed to further elucidate if 
sphingolipids in SS MPs are solely responsible for the increased cathepsin activity.  
If the bone loss in SCD is due to increased osteoclastogenesis and/or osteoclast 
activity has been up for debate. In adult and pediatric SCD patients, TRACP 5b, an 
enzyme that is a marker of osteoclast activity, is increased in the serum [208, 216]. 
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However, in female SS mice, the mRNA for TRAP was decreased in comparison to 
control, and there was no increase in the bone resorption marker CTX-1 [134]. Moreover, 
increased osteoclast activity and osteoclast differentiation in sickle mice was surmised 
through upregulation of the genes RANK and RANKL, respectively, as well as through 
the increase in the number of osteoclasts present on the femoral bone surface [137]. In 
this work, we found evidence of increased osteoclastogenesis and activity in SCD. BM 
cells cultured from AA and SS femurs resulted in increased osteoclast differentiation in 
SS samples (Figure 4.4E). Furthermore, by the appearance of the cells, SS cells appeared 
to differentiate into full activated osteoclasts, apparent by the presence of a ruffled 
border, while AA cells look to be more so in the multinucleated osteoclast stage of 
osteoclastogenesis [184]  (Figure 4.4C-D). Xiao et al. reported that SS osteoclasts did not 
have an increase in bone resorption activity in vitro [134]. However, our data display 
increased osteoclast activity through the increased presence of TRAP in the distal end of 
SS femurs (Figure 4.4J-L). Increased osteoclast activity in SCD is further demonstrated 
in increased cathepsin activity and cat K expression shown via enzyme zymography and 
western blot (Figure 4.4F-I). Additionally, we see no proteases activity at any molecular 
weight with the addition of the cysteine cathepsin inhibitor E-64 (Figure 4.5A). 
Zymography and Western blot data taken together suggests that the higher active bands 
(175kDa, 150kDa) in the zymography are cat K. The Western shows expression of 
mature cat K in addition to increased expression of heavy chain versions of cat K in SS 
(and one AA) BM-derived osteoclasts, which provides insight as to why we see increased 
activity in SS osteoclasts at 175kDa and 150kDa in the zymography gel (Figure 4.4F, H). 
With the addition of a cat K inhibitor, activity at 175kDa disappears for AA and SS 
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osteoclasts while the signal at 150kDa only diminishes for SS osteoclasts (Figure 4.5B-
C). This data shows that indeed the increased cathepsin activity in SS osteoclasts in 
Figure 4.4F-G at 175kDa and 150kDa is cat K.  Future studies are needed to fully 
elucidate if the higher bands in the zymography are potentially cat K bound to tissue, 
causing for its activity to show up in the gel at molecular weights higher than the 
anticipated 75kDa. Additionally, the higher bands in the Western are potentially pro-
cathepsin K that has not been fully cleaved by other proteases to be fully active, or 
mature. This deduction is further supported by recombinant cat K being present at 
150kDa. Our data demonstrates that SS BM- derived osteoclasts produce more cat K 
compared to AA BM-derived osteoclasts. This gives some in sight about cat K 
production in SCD and gives a discernible reason for the decreased bone density that 
plagues sickle patients.  
Our BMT studies further substantiate our inference that the increased cathepsin 
activity in SS osteoclasts and PBMCs contribute to the bone loss in SCD. Keegan et al. 
found that there is increased cat K activity in SS endothelial cells [17]. We wanted to 
demonstrate that the cathepsin activity present within cells of a hematological lineage 
contributes to SBD and not the cathepsins from stromal cells. When we reconstituted the 
BM of wild-type mice with AA and SS BM, we saw a decrease in Cort. Th. and 
trabecular BV/TV in mice that received SS BM in comparison to those that received AA 
BM (Figure 4.10C, E). However, even when cat K is genetically knocked down, we still 
see a significant decrease in the aforementioned bone parameters in Cat K-/- mice given 
SS BM in comparison to those given AA BM (Figure 4.10C, E). This demonstrates that 
even when cat K is not active in the stromal cells, there is still bone loss present due to 
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the overactive cathepsins in the hematological cells in SS BM. Overall, our data 
demonstrates that cathepsins should be targeted to reduce the bone loss present in SCD.  
 By inhibiting cysteine cathepsins with E-64 treatment, we saw an increase in 
cortical and trabecular bone in sickle mice. In previous studies combating osteoporotic 
bone loss, inhibition of cat k has been the main strategy [217-219]. However, a total 
genetic knockout of cat K has been shown to increase the production of other proteases 
such as matrix metalloproteinases (MMPs), modify osteoblast function, and lead to brittle 
bones [127, 220]. This finding is possibly due to the fact that, even though at minor level, 
osteoblasts produce cathepsin K [221]. Furthermore, in humans there is a lysosomal 
disease called pycnodysostosis that is caused by a mutation in the cat K gene; people with 
this disorder have increased bone density but suffer from brittle bones [123]. 
Additionally, osteoclasts use cathepsins other than cat K such as B and L to resorb bone 
in mice and rats  [73, 127, 222]. Moreover, broad cysteine cathepsin inhibition had a 
significant reduction in the amount of digested bone matrix in comparison to a specific 
cat K inhibitor [127]. Therefore, we utilized the drug E-64, which inhibits the activity of 
several cysteine proteases such as cathepsin K, S, L, B, and H to attenuate the bone loss 
in SCD [223]. In 3-month old mice, SCD caused for decreased Cort. Th., BA, BA/TA, 
and BMD within the mid diaphyseal region (Figure 4.6C, E, G, I). According to Bonnet 
et al., the strength of bones primarily comes from the Cort. Th. and BA [147]. 
Unsurprisingly, SS femurs were able to withstand significantly less force and stress in 
comparison to AA and AS bones during four-point bending mechanical testing (Figure 
4.9B-C). E-64 treatment increased Cort. Th., BA, and BA/TA in SS mice (Figure 4.6D, 
F, H). Consequentially, this enhancement in cortical bone structure due to E-64 treatment 
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leads to improved mechanical properties in SS bones. In regard to the relationship 
between the Cort. Th. and the mechanical properties of stiffness, ultimate stress and max 
force, SS femurs have a negative correlation; this shows that as stiffness, maximum force 
or ultimate stress increases, the Cort. Th. decreases. However, with E64 treatment, SS 
femurs had a significant positive correlation of their Cor. Th.  to the latter two 
aforementioned properties (Figure 4.9E-F). A similar pattern was observed for stiffness 
and BA/TA, but E-64 resulted in a positive although not significant correlation (Figure 
4.9G-I). Furthermore, other studies have shown that the mechanical strength of bone can 
also vary due to changes in trabecular architecture [171]. In the distal end of the femur, 
SS mice have reduced Tb. Th. and BMD in the epiphyseal but not the metaphyseal region 
(Figure 4.7C, E, Figure 4.8 C, E). This difference could be due to the fact that the distal 
epiphysis in mice is nourished from an independent vasculature from the metaphysis until 
5 months of age [130]. This would cause the epiphysis to be at an elevated risk for vaso-
occlusions that would result in bone loss. E-64 treatment significantly increased Tb. Th. 
and BMD in the distal epiphysis in SS mice (Figure 4.7D, F). Overall, E-64 treatment 
lead to increased cortical and trabecular bone and thus increased mechanical strength of 
SS femurs; this demonstrates that the inhibition of cysteine cathepsins is a viable target to 
attenuate SBD. 
 In conclusion, we have shown that there is a mechanistic link between the 
dysregulation in sphingolipid metabolism and increased cathepsin activity that leads to 
bone loss in SCD. We have made the novel discovery that targeting cathepsin activity is a 
viable treatment to attenuate bone loss, especially within the cortical bone, in SBD.  
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CHAPTER 5  Novel Lipid Signaling Mediators for Mesenchymal 
Stem Cell Mobilization During Bone Repair2 
5.1 Abstract 
 Mesenchymal stem and progenitor cells (MSCs), which normally reside in the 
bone marrow, are critical to bone health and can be recruited to sites of traumatic bone 
injury, contributing to new bone formation.  The ability to control the trafficking of 
MSCs provides therapeutic potential for improving traumatic bone healing and therapy 
for genetic bone diseases such as hypophosphatasia. In this study, we explored the 
sphingosine-1-phosphate (S1P) signaling axis as a means to control the mobilization of 
MSCs into blood and possibly to recruit MSCs enhancing bone growth. Loss of S1P 
receptor 3 (S1PR3) leads to an increase in circulating CD45-/CD29+/CD90+/Sca1 
putative mesenchymal progenitor cells, suggesting that blocking S1PR3 may stimulate 
MSCs to leave the bone marrow. Antagonism of S1PR3 with the small molecule 
VPC01091 stimulated acute migration of CD45-/CD29+/CD90+/Sca1+ MSCs into the 
blood as early as 1.5 hours after treatment. VPC01091 administration also increased 
ectopic bone formation induced by BMP-2 and significantly increased new bone 
formation in critically sized rat cranial defects, suggesting that mobilized MSCs may 
home to injuries to contribute to healing. We also explored the possibility of combining 
                                                 
 
 
2 Adapted from: J.M. Selma, A. Das, A.O. Awojoodu, T. Wang, A.P. Kaushik, Q. Cui, H. Song, M.E. Ogle, 
C.E. Olingy, E.G. Pendleton, K.F. Tehrani, L.J. Mortensen, E.A. Botchwey, Novel Lipid Signaling 
Mediators for Mesenchymal Stem Cell Mobilization during Bone Repair, Cell Mol Bioeng 11(4) (2018) 
241-253. Reprinted with permission from Springer Nature  
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S1P manipulation of endogenous host cell occupancy with exogenous MSC 
transplantation for potential use in combination therapies. Importantly, reducing niche 
occupancy of host MSCs with VPC01091 does not impede engraftment 
of exogenous MSCs. Our studies suggest that MSC mobilization through S1PR3 
antagonism is a promising strategy for endogenous tissue engineering and improving 
MSC delivery to treat bone diseases. 
5.2 Introduction  
After traumatic bone injury, including long bone fractures and ischemic injuries, a 
population of MSCs exit the bone marrow (BM) and migrate to the wound to differentiate 
into osteoblastic cells and support new bone formation [75, 76, 224, 225]. The 
mobilization and recruitment of these cells are critical phases of tissue regeneration and a 
decreased mesenchymal stem cell (MSC) response is correlated with deficits in bone 
healing in human patients [73, 226, 227]. Dysfunction of MSCs through genetic defects 
such as in hypophosphatasia can also lead to improper bone development and 
homeostasis [228]. Delivery of exogenous BM-derived MSCs after bone injury enhances 
repair [229-231]. However, exogenous cell-based therapies are not widely available yet, 
can be time-intensive, and cost-prohibitive. Since there is an established role for MSCs in 
bone tissue repair, we sought to increase their mobilization and recruitment to the defect 
site to enhance bone healing. We also pursued utilizing endogenous MSC mobilization as 
a method to enhance the engraftment of exogenous MSCs in the BM. 
Sphingosine 1-phosphate (S1P) is a biologically active signaling lipid that is 
present at high concentrations in blood where it binds to serum albumin or high-density 
lipoproteins. It binds to 5 high affinity G-coupled receptors (S1PR1-S1PR5) that direct a 
 97 
wide range of biological processes [59, 62, 232-235] such as a chemoattractant for many 
cell types including MSCs [18, 19] and hematopoietic stem cells, guiding their egress 
from BM into the peripheral blood (PB) along the S1P gradient [20-22]. While the 
network of S1PR signaling is extremely complex, S1PR1 and S1PR3 in particular, have 
been shown to have significant effects on stem cell homing and mobilization. BM-
derived cells are recruited by S1PR3 to inflamed tissues and induce a reduction in 
proinflammatory cytokine secretion and microvascular remodeling [95]. SEW2871, an 
S1PR1 agonist, enhances the motility and mobilization of osteoclast precursors in vivo 
and regulates bone homeostasis[62]. S1PR3 activation on human endothelial progenitor 
cells (EPCs) resulted in phosphorylation of the chemokine receptor 4 (CXCR4) and 
enhanced SDF-1 mediated chemotaxis and homing to ischemic tissues [61]. S1PR3 
activation with a small molecule analogue of sphingosine, FTY720, resulted in enhanced 
CXCR4 function in hematopoietic stem and progenitor cells (HSPCs) in vitro and in vivo 
as well as enhanced homing and proliferation [94]. Recently, we found that antagonizing 
S1PR3, which phosphorylates CXCR4, mobilizes HSPCs out of the BM and into 
circulation [96].  Since MSCs express CXCR4, we hypothesized that S1PR3 antagonism 
could be utilized to mobilize MSCs as well [236].   
In this study, we show that use of VPC01091 [237], a small molecule analogue of 
S1P that is a weak agonist of S1PR1 and strong antagonist of S1PR3, in a systemic 
manner enhances the mobilization of progenitor and mesenchymal stem cells and favors 
mesenchymal stem mobilization over hematopoietic stem cell mobilization. Using a 
subcutaneous bone formation assay, we demonstrate that osteogenic differentiation of the 
progenitor cells contributes to this process. We also determined that VPC01091 
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administration increases new bone formation in critical size cranial defects. In this work, 
we demonstrate for the first time that utilizing small molecule antagonism in S1PR3 
signaling is sufficient for rapidly mobilizing MSCs into the PB and has broad 
implications for advancing therapy for bone fractures/defects and bone metabolic 
diseases. 
5.3 Materials and Methods 
5.3.1 Animals 
 Animal surgeries and procedures were performed in accordance and with approval 
from the University of Virginia, Georgia Institute of Technology, or University of Georgia 
Institutional Animal Care and Use Committees. Murine model studies were performed using 
C57BL/6 male mice from Jackson Laboratories and S1PR3 knockout mice (S1PR3-/-) on 
C57BL/6 background (a kind gift of Dr. Richard Proia at the National Institutes of Health). 
The subcutaneous ectopic bone model and the cranial defect model were performed in female 
Sprague Daley rats aged 8-10 weeks which were obtained from Charles River Laboratories 
International, Inc. (Wilmington, MA).  
5.3.2 Analysis of MSC and LSK Mobilization  
 C57BL/6 or age-matched S1PR3-/- mice were euthanized by CO2 inhalation. PB 
was harvested by cardiac puncture. For analysis of MSC trafficking in response to S1P 
signaling and other small molecules, mice were injected intraperitoneally (IP) with 5 
mg/kg AMD3100 (Sigma) in saline or VPC0109 (Avanti) or FTY720 (Cayman 
Chemical) in sterile saline with 5% DMSO, 3% fatty-acid-free bovine serum albumin. 
For MSC trafficking time course analysis, C57BL/6 mice were treated IP with 5 or 10 
mg/kg of VPC01091, and PB was collected by jugular vein draw at 1.5, 3, or 24 hours 
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after anesthesia. After blood collection, red blood cells were lysed with ammonium 
chloride, and PB mononuclear cells were stained for FACS analysis. Flow cytometry 
immunophenotyping was performed according to standard procedures and was analyzed 
on a CyAn ADP flow cytometer or BD FACS Aria II cytometer. Fluorophore conjugated 
monoclonal antibodies to Sca1, CD45, CD105, CD11b, CD90, and/or CD29 were used in 
studies to identify MSCs while antibodies for stem cell antigen-1 (Sca1), C-kit, and 
Lineage were used for LSK (Lineage- Sca1+ C-kit+) cells. The absolute number of cells 
mobilized were determined by utilizing AccuCheck Counting Beads (Thermo).  
5.3.3 S1PR1 and S1PR3 Expression  
 S1PR1 and S1PR3 expression was measured by western blotting utilizing 
antibodies (S1PR1/EDG-1, S1PR3/EDG-3, Novus Biologicals) against the sphingolipid 
receptors. An equivalent quantity of protein from each group was injected into the gels 
and the bands were stained with near IR dyes 
5.3.4 Ectopic Bone Model 
 Sprague Daley rats of age 8-10 weeks were anesthesia with isoflurane gas and 
continued with Ketamine/Xylazine (80/8 mg/kg via IP injection). To study ectopic bone 
formation, rats were injected subcutaneously, as described by Scott et al., with a Matrigel 
plug doped with BMP-2 [238]. Rats were randomly assigned to three different groups: 
control-subcutaneous Matrigel plug with BMP-2 only; subcutaneous Matrigel plug with 
BMP-2 plus a systemic IP dose of 1 mg/kg or 5 mg/kg VPC01091 (Lynch lab) every other 
week. Tissue surrounding the Matrigel was taken at week 1 and week 3 following 
implantation and digested for flow cytometry. At the end of 6 weeks, the ectopic implants 
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were removed, and the bone volume was measured with micro-computed tomography 
(microCT). 
5.3.5 Cranial Defect Model 
 Following anesthetization, cranial defect surgery was performed as previously 
described [239, 240]. Briefly, after sterilization, a longitudinal incision was made through 
skin and periosteum, over the dorsum of the skull. The periosteum was reflected laterally. A 
3-mm round burr was used to create an 8-mm defect in the bone with constant saline 
irrigation using a Hall® Surgical E900® System and Coolflex® High Speed Drill 
(CONMED Linvatec, Largo FL). The animals were treated with an IP dose of 1 mg/kg 
VPC01091 (Lynch lab) 24 hours and 3 weeks after surgery or left untreated for control. In all 
cases, the periosteum was closed with a 5-0 running nylon suture. The skin was closed with a 
running subcuticular vicryl suture, and VetClose™ (Butler Animal Health Supply, Dublin 
OH) was applied on the incision. Ketoprofen (3 mg/kg SC) was given after closure and for 
three days post-surgery to minimize pain. Rats were given free access to food and water and 
monitored for complications or abnormalities. At 9 weeks post-surgery, rats were 
anesthetized with 2.5% isoflurane gas and injected in the heart with 1 mL Nembutal for 
euthanasia. 
5.3.6 Histology 
 Calvarial bones were extracted, fixed in 10% buffered formalin for 7 days and 
decalcified using an HCl and EDTA decalcifying solution (Richard-Allan Scientific, 
Kalamazoo MI) for 3 days at 4oC. The calvarial bones were cut in half, perpendicular to the 
sagittal suture and centered at the defect. The rostral section was embedded in paraffin and 
sliced and stained with Mason’s Trichrome.  Bone sections were then washed and mounted 
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with PBS and glycerol solution (1:1) and visualized under a bright field microscope for 
positive staining. All images were evaluated by a blinded researcher.    
5.3.7 MicroCT Analysis   
 MicroCT of the ectopic bone formation was conducted on explanted tissue after 
sacrifice. MicroCT of for the critical-sized defect studies was performed longitudinally at 
weeks 2, 4, 6 and 8 under ketamine/ xylazine induced anesthesia. 2D images were segmented 
by drawing the region of interest to comprise only parietal bone by including all bone inside 
the ridges separating parietal from temporal bone. Animals were scanned with the following 
parameters: 38 μm voxel size, 55 kVp, 145 μA, medium resolution, 38.9 mm diameter field 
of view, and 200 ms integration time (73 mGy radiation per scan). Slice number was set for 
each animal throughout the study to include the whole defect and an equal length both 
anterior and posterior of the defect (≈300 slices). Bone was thresholded at 470.1-1000 mg 
hydroxyapatite (HA)/cm3, and bone volume was measured with the microCT software. 3D 
volume renderings were either done with SCANCO software after segmentation, or OsiriX 
3.9 (Pixmeo, Geneva, Switzerland) from DICOM files of the region of interest. OsiriX 
images were thresholded and colored appropriately with the 16-bit color look up table 
(CLUT). All images were evaluated by a blinded researcher. 
5.3.8 MSC In Vitro Culture 
 MSCs from 6-week-old wild type C57BL/6 mice were isolated according to a 
previous protocol [186]. Briefly, filtered BM-derived cells were collected in alpha-MEM 
media supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-
streptomycin (Gibco), and plated in a tissue culture flask at 1.5x106 cells/cm2. The media 
was changed every 3-4 days and cells were passaged at 60-80% confluence.  
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5.3.9 BM Niche Pre-clearance for MSC Engraftment 
 C57BL/6 mice aged 6-8 weeks were obtained from Jackson Laboratories. Mice were 
treated IP with saline or 5 mg/kg of VPC01091 (Avanti) in saline containing 5% DMSO and 
3% fatty-acid-free BSA. Three hours later, MSCs (isolated and cultured from 6-week-old 
C57BL/6 mice BM) stained with lipophilic DiD membrane dye according to manufacturer 
protocols (Invitrogen) were injected into the retro-orbital sinus at a dose of 1x105 cells per 
20g of recipient mouse weight. Mice were euthanized 24 hours later, and the craniums were 
imaged with 2-photon microscopy to quantify MSC engraftment. 
5.3.10 Optical Setup 
A custom-built two-photon microscope was used. [241-243]. A 1550 nm, 370 
femtosecond pulsed fiber laser (Calmar Cazadero) with wavelength of 1550 nm and 
repetition rate of 10 MHz was used. The beam was frequency doubled using a second 
harmonic generation (SHG) crystal (Newlight Photonics), to produce a 150mW 775 nm 
beam for two-photon excitation of the sample. Beam power was modulated using a 
Pockels cell (Conoptics) and scanned over the sample by a resonant-galvanometer (fast 
axis – slow axis) scanner (Sutter instruments MDR-R), which enables imaging at a rate of 
30 frames per second. A 60x Olympus (LUMFLN60x) water immersion objective with 
NA of 1.1 was used for imaging. Z-scanning was performed using an X-Y-Z stage from 
the Sutter Instruments (MPC-200).  MSCs stained with DiD were imaged using a 697/58 
nm filter, autofluorescence from the endogenous bone marrow cells were captured using 
a 525/50 nm filter, and second harmonic generation from bone collagen fibers was 
measured using a 390/18 nm filter. Photon multiplier tubes (PMTs) from Hamamatsu 
were used for collection of the signal, and their signal amplified with a transimpedance 
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amplifier (Edmund Optics 59-178). A National Instruments DAQ card and FPGA module 
were used for control and synchronization of the system and digitizing of the amplified 
SHG signal. MATLAB-based Open-source software Scanimage [244] was used to 
control the microscope.  
5.3.11 Statistical Analysis 
 Statistical comparisons were performed utilizing GraphPad Prism (La Jolla, CA). 
The resulting analysis is conveyed as mean ± standard error of the mean (SEM).  Two-
tailed t-test was used for column analysis. For grouped analyses, one-way ANOVA with 
Holm-Sidak’s multiple comparison test was utilized. For grouped analyses comparing 
data over time or between treatment and control, two-way ANOVA with Tukey's 
multiple comparisons test was used.  A p-value less than 0.05 was considered statistically 
significant.  
5.4 Results 
5.4.1 The S1P signaling axis controls progenitor cell trafficking from the BM 
Due to our previous finding that S1PR3 plays a role in hematopoietic stem and 
progenitor cell (HSPC) retention within the BM niche, we hypothesized that S1PR3 may 
play a similar role in other progenitors such as MSCs and that the loss of S1PR3 
mobilizes them into the blood. To analyze circulating progenitor cells by flow cytometry, 
blood was drawn from wild type and S1PR3-/- mice. S1PR3-/- mice have a significantly 
higher proportion of  Sca1+ (a marker widely expressed on progenitor populations of the 
BM including MSCs and HSPCs[245]) cells in the PB compared to age matched wildtype 
controls (Figure 5.1A) and similarly display a larger percentage of CD45-
/CD29+/Sca1+/CD90+ cells (MSCs) in the blood (Figure 5.1B) via the gating strategy 
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depicted in (Figure 5.2A-D). Acute pharmacological targeting of S1PR3 with a small 
molecule antagonist, VPC01091 [237], significantly enhanced the percentage of Sca1+ 
progenitor cells in the blood of  wild type mice compared to AMD3100 (a CXCR4 
antagonist and known stem cell mobilizer) while FTY720, an agonist of S1PR3, reduced 
Sca1+ progenitor cell circulation (Figure 5.1C).  
 
Figure 5.1. Genetic and pharmacological S1PR3 suppression mobilizes progenitor 
cells into circulation. (A) S1PR3-/- mice show an increase in percentage of Sca1+ (n=3 
mice per group) and (B) CD45-/C29+/CD90+/Sca1+ cells in circulation (n=4 mice per 
group). (C) The percentage of Sca1+ cells mobilized into circulation increases in one 
hour by pharmacological S1PR3 antagonism via VPC01091 (n=4 mice per group). Data 
expressed as mean ± SEM. *p<0.05. Abbreviations: WT, wild type; Sal, saline; AMD, 




Figure 5.2. Flow cytometry gating for MSCs. MSCs are identified in the blood by 




Additionally, BM cells were harvested from wild type mice and Sca1+/CD105+ cells 
were sorted via FACS. Western blotting was used to detect S1PR1 and S1PR3 
expression. Both receptors were present in these mouse mesenchymal cells (Figure 5.3A).  
In order to determine if Sca1+/CD105+ cells were in the pool of cells in the PB of 
S1PR3-/- mice, we employed antibodies against Sca1 and CD105, putative murine MSC 
markers. We quantified the proportion of Sca1+/CD105+ cells in blood and found that, 
similar to Sca1+ progenitors, untreated S1PR3-/- mice showed an increase in 




Figure 5.3. S1P receptor expression for MSCs. (A) Sca1+/CD105+ cells isolated from 
wild type mice express relatively more S1PR3 compared to whole bone marrow cells. (B) 
S1PR3-/- mice have more Sca1+/CD105+ cells in circulation (n=2 mice per group). 
 
 
5.4.2 Systemic antagonism of S1PR3 increases MSC mobilization   
 To further examine whether pharmacological inhibition of S1PR3 could mobilize 
MSCs into the PB, we treated wildtype C57BL/6 mice with 5 mg/kg or 10mg/kg doses of 
VPC01091 (Figure 5.4A-B).  
 
Figure 5.4. VPC01091 increases the mobilization of MSCs into circulation. (A) 
Schematic of animal studies. (B) 5 mg/kg of VPC01091 increases the number of CD45-
/C29+/CD90+/Sca1+ cells (MSCs) in the blood after 1.5 hours in comparison to control 
and 10mg/kg of VPC01091 (n=3-4 mice per group). (C) Schematic of animal studies. (D) 
The number of CD45-/C29+/CD90+/Sca1+ cells (MSCs) in the blood increases 
following twenty-four hours after 5mg/kg VPC01091 dose (n=4 mice per group). Data 
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expressed as mean ± SEM. * p<0.05. Abbreviations: WT, wild type; BM, bone marrow; 
VPC, VPC01091; mpk, milligram per kilogram; I.P., intraperitoneal. 
 
 
VPC01091 increased the number of MSCs in the blood at a concentration of 5 mg/kg. 
Similarly, we tested these dosages on the effect of mobilizing LSK (Lineage-/Sca1+/C-
kit+) cells and observed a significant increase in the number of MSCs mobilized in 





Figure 5.5. VPC01091 increases the mobilization of MSCs into circulation over LSK 
cells. (A)5mg/kg of VPC01091 increases the mobilization of MSCs into the blood more 
than LSK cells (n=4 mice per group). LSK cells are identified in the blood by gating for 
(B) cells, (C) single cells, (D) lineage- cells and (E) Sca1+/C-kit+ cells. Data expressed 




To further examine whether pharmacological inhibition of S1PR3 could mobilize MSCs 
into the PB over a longer time course, wildtype C57Bl/6 mice were treated with vehicle 
control or 5 mg/kg VPC01901 by IP injection and tracked the expression of CD45-
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/Sca1+/CD90+/CD29+ cells in the blood at 0, 3, and 24-hour intervals after injection ( 
Figure 5.4C-D). MSCs were increased in the blood at 24 hours after (Figure 5.4D) by 
utilizing the gating strategy depicted in (Figure 5.2A-D).  
5.4.3 Systemic antagonism of S1PR3 increases ectopic bone formation   
Since MSCs have osteogenic potential, we investigated whether VPC01091 has 
an effect on ectopic bone formation. In Sprague Daley rats, we performed an ectopic 
bone assay with BMP-2 laden matrigel. Under control conditions, after 6 weeks, a very 
small amount of mineralized bone is formed in the BMP-2 matrigel implant. However, if 
VPC01091 is injected once weekly over the 6-week experiment, there is substantially 
increased bone formation as measured by microCT imaging (Figure 5.6A-C).  
 
 
Figure 5.6. Amount of ectopic bone 6 weeks after matrigel + BMP-2 implantation 
increases with weekly systemic VPC01091 treatment. (A) Schematic of animal studies. 
(B) Representative MicroCT images of ectopic bone after 6 weeks of 1 or 5 mg/kg dose 
of VPC01091. (C) Every other week treatment of 1 or 5 mg/kg of systemic VPC01091 
increases the ectopic bone formation in the presence of BMP-2 (n=6 mice per group). 
Data expressed as mean ± SEM. * p<0.05. Abbreviations: BMP-2, bone morphogenetic 
protein 2; VPC, VPC01091; mpk, milligram per kilogram.  
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Moreover, the tissue surrounding the ectopic bone site shows an increased recruitment of 
CD29+/CD90+ cells at weeks 1 and 3 post implantation (Figure 5.7A-B). This suggests 
that systemic delivery of VPC01091 encourages ectopic bone formation and that this 




Figure 5.7. More MSC-like cells migrate to ectopic bone site with systemic 
VPC01091. Percentage of CD29+/CD90+ cells surrounding ectopic bone site increases 
with systemic VPC01091 treatment at 1 week (A) and (B) 3 weeks after matrigel + BMP-
2 implantation (n= 3 mice per group). Data expressed as mean ± SEM. * p<0.05. 
Abbreviations: VPC, VPC01091; mpk, milligram per kilogram. 
 
 
5.4.4  S1PR3 antagonism improves regeneration of a critical-sized bone defect  
To further explore S1PR3 antagonism as a means to enhance bone forming 
capacity, we tested the effect of systemic VPC01091 treatment after a critical sized 




Figure 5.8. Systemic therapy with VPC01091 (at week 0 and week 3) after critical-
sized cranial defect results in an increase in defect site bone volume. (A) Schematic 
of animal studies. (B) Representative MicroCT images before and 8 weeks after cranial 
defect surgery. (C) Systemic treatment with 1 mg/kg of VPC01091 increases bone 
volume at defect site at 8 weeks (n=4-9 mice per group). Data expressed as mean ± SEM. 
*p<0.05 week 8 empty compared to week 2 empty, week 8 VPC01091 compared to week 





Rats were treated with either vehicle or 5mg/kg VPC01091 on the day of the defect 
surgery and again at 3 weeks following the surgery. After 8 weeks, the animals treated 
with VPC01091 demonstrated increases in the amount of new bone formation by 
microCT analysis (Figure 5.8B-C) and Masson’s trichrome histology (Figure 5.9). 
Histological evaluations show animals treated with VPC01091 had tissue in the defect 
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region that appears more like regenerating bone, including the presence of more osteoid 
bodies and more collagen than in the control animals (Figure 5.9A-D). 
This treatment does not require any local implants and is modulated by the fact that 
VPC01091 mobilizes stem and progenitor cells from the bone barrow into circulation. 
These cells can then be recruited to the defect site where they can differentiate into bone. 
Moreover, CD90+/ CD11b- cells were recruited to the defect site in animals that received 
the systemic dose of VPC01091 (Figure 5.9E).  
 
 
Figure 5.9. Increase in osteoid body formation and fibroblast-like cell migration to 
defect site with systemic VPC01091. Representative images of Masson’s trichrome 
staining of calvarial bone after 8 weeks of saline (A) or 1 mg/kg VPC01091 treatment (C) 
showing osteoid bodies (red) within the bone (blue). Magnified sections (squared off 
segments in A, C) of Masson’s trichrome staining of calvarial bone after 8 weeks of 
saline (B) or 1 mg/kg VPC01091 treatment (D). (E) 3 weeks after treatment, there is an 
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increase in the percentage of CD90+ and CD11b-/CD90+ cells in the defect region (n=3 
mice per group). Data expressed as mean ± SEM. * p<0.05.  
 
5.4.5 S1PR3 antagonism to pre-clear the BM niche does not impede donor MSC 
engraftment  
With bone fractures and some metabolic bone diseases being treated via MSC 
therapies, we were interested to see the effect that VPC01091 has on allogenic MSCs 
homing to bone.  An injection of VPC01091 three hours before MSC administration 
yielded transplanted MSC engraftment into the cranial bone of wild-type mice (Figure 
5.10A-B). Importantly, treatment with VPC01091 did not impede external MSC 
engraftment (p=0.4905).  DiD stained MSCs were visualized in the skull 24 hours after 
injection (Figure 5.10C-D). This data suggests that manipulating sphingolipid signaling 
in order to mobilize endogenous BM-residing MSCs can be utilized in a combination 
with delivering allogenic MSCs without damaging the host bone marrow or 





Figure 5.10. Mobilizing endogenous MSCs with VPC01091 does not inhibit 
transplanted MSC engraftment into bone. (A) Schematic of animal studies. (B) 
Number of donor MSCs engrafted per mouse into the cranial bone does not increase 24 
hours after 5 mg/kg treatment of VPC01091 (n=3 mouse per group). Representative 
images of donor DiD-stained engrafted into the cranial bone of host mice 24 hours after 
saline (C) or 5 mg/kg VPC01091treatment (D). Green cells are endogenous bone marrow 
cells. Red cells are transplanted MSCs, quantified in the bone marrow cavities (indicated 
by arrow with dotted line borders). Cyan colored areas are second harmonic generation 
signal from bone collagen. Data expressed as mean ± SEM. Abbreviations: VPC, 
VPC01091; mpk, milligram per kilogram.  
 
 
5.5 Discussion  
 Autologous or allogenic bone grafts are the gold standard remedies to repair 
critical-size bone defects; however, there are several limitations. In addition to causing 
chronic residual pain, autografts harvested from patients’ iliac crests have up to a 20% 
chance of causing major complications such as pelvic instability, nerve injury, and 
haematoma formation [246]. Due to the risk of transmitting disease, allografts have to 
undergo a sterilization process that affects the structural integrity and eliminates the 
intrinsic osteogenic potential of the grafts [246, 247]. As an alternative, researchers have 
 115 
investigated cellular approaches to bone tissue engineering, such locally implanted 
autologous MSC-seeded constructs [248]. Despite some debate in MSC therapy leading 
to vascular calcification, utilizing MSCs over other stem cell types such as embryonic 
stem cells is advantageous in that they can be isolated from various sources including but 
not limited to BM, adipose tissue, dental pulp, and PB [249, 250]. However, it takes an 
estimated 4-6 weeks to obtain enough MSCs for clinical application [249]. Additionally, 
long-term in vitro culture of MSCs decreases their mineralization and 
immunosuppression capacity [251, 252].  Hence, research studies have begun to place 
emphasis on finding a therapy to quickly mobilize and amplify a patient’s own 
endogenous stem cells to the site of the bone injury.   
The presence of MSCs in PB is controversial. Hoogduijn et al. claimed that 
human patients with organ injury had no circulating MSCs unless the bone marrow cavity 
was broken open by way of a skeletal fracture [253]. However, Kassis et al. discovered 
that with the use of G-CSF, MSCs could be isolated from human PB with the use of 
fibrin microbeads [254]. Furthermore, MSCs taken from the PB were found to be 
successful in contributing to new bone formation in cranial critical sized defects in 
Sprague Dawley rats [255].  Future studies will be required to track endogenous MSCs 
after administering VPC01091 to a cranial defect site, utilizing our previous cell tracking 
methods, to verify that the new bone formation we witnessed with VPC01091 
administration in  Figure 5.6 and Figure 5.8 is indeed due to mobilized MSCs [256].  
Additional studies will also be required to examine whether mobilized cells give rise to 
mesenchymal lineages such as osteocytes, chondrocytes, and adipocytes in vitro as do 
MSCs from other tissue depots such as BM and adipose tissues.  
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 A steep gradient of S1P exists between BM and blood and is used by many cell 
types to navigate the path from marrow to circulation [21, 60, 62, 96, 257]. MSCs, 
osteoprogenitors, and osteoclast progenitors express S1P receptors and are 
chemotactically sensitive to S1P gradients [18, 62, 70] and biomaterial strategies 
incorporating S1P receptor targeting molecules increase bone regeneration [239, 240, 
258-260]. We have recently demonstrated that S1PR3 is a critical signal for HSPC 
retention within the BM niche and that loss or antagonism of S1PR3 mobilizes these cells 
to the blood [96]. Additionally, we discovered that HSPCs and MSCs have different 
relative expression levels of S1PR1and S1PR3 mRNA [96]. Because MSCs may react 
distinctively to S1P signalling, we utilized flow cytometry to determine that S1PR3 -/- 
mice have an increased basal level of circulating progenitor cells in comparison to 
wildtype (Figure 5.1A). We therefore hypothesized MSCs can be mobilized into the 
blood through pharmacological inhibition of S1PR3 by VPC010191 treatment and serve 
in bone repair.  
It has been speculated that due to their greater size and superior ability to remain 
in their stem cell niche, MSCs are more difficult to mobilize than HSPCs [261]. 
However, in this study we were able to demonstrate with VPC01091 that we can 
mobilize a greater number of MSCs into circulation in comparison to LSK cells (Figure 
5.5A). For these in vivo mobilization studies, we utilized a single isomer (3d-P) of 
VPC01091 that has greater inhibitory activity at S1PR3 and little to no activity at S1PR1 
[237]. This finding can possibly be explained by the results in (Figure 5.3A) that show 
more relative expression of S1PR3 in cells positive for the MSC markers Scal and CD105 
in comparison to whole bone marrow cells. Furthermore, we verified through flow 
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cytometry that 5mg/kg of VPC01091 transiently induces mobilization of CD45-
/CD29+/C90+/Sca-1+ cells (MSCs) as early as 1.5 hours after injection (Figure 5.4B).  
Interestingly, at 3 hours the level of MSCs in the blood drops and then increases again at 
24 hours (Figure 5.4D). This suggests that the cell population is traveling to other parts of 
the body, but the location is unclear.  It has been found that BM-derived MSCs migrate to 
sites of injury to aid in tissue repair and regeneration in various kinds of wounds 
including myocardial infarction and bone fracture [236]. Therefore, we utilized a cranial 
defect model to test whether mobilized MSCs were indeed moving to an injured site.  
Through microCT imaging, we determined that injections of VPC01091 at week 0 and 
week 3 increased bone volume and CD90+ cells at the defect site (Figure 5.8C, Figure 
5.9E). Furthermore, ectopic bone development created by BMP-2 releasing matrigels was 
enhanced due to cells mobilized by VP01091 (Figure 5.6C). According to Otsuru et al., 
there is a mechanistic links between osteoprogenitors circulating in the blood and the 
formation of ectopic bone via BMP-2 [93]. Additionally, VPC01091 treatment increased 
the percentage of CD29+/CD90+ cells present in the tissue surrounding the matrigel as 
early as one-week post-implantation (Figure 5.7A-B).  This combined data suggests that 
bone-forming MSCs are capable of being mobilized from the bone marrow niche through 
S1P signalling. 
Recently, Fu et al utilized G-CSF in rabbits to mobilize MSCS into the blood to 
be harvested and cultured to treat osteonecrosis (ON) [81].  Deng et al. mobilized MSCs 
with G-CSF into the PB and found that they can aid in repair of injured cerebral tissue 
[82]. However, in certain populations, such as cancer patients undergoing chemotherapy 
or other hematological disorders, G-CSF has proven to be an ineffective drug [83-85]. 
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MSCs are positive for the chemokine receptor 4 (CXCR4), which aids in the stem cells 
remaining in the SDF-1 rich BM.  AMD3100, being a CXCR4 antagonist, can therefore 
disturb this linkage and mobilize MSCs into circulation. Toupadakis et al., showed that 
AMD3100 treatment increased the number of MSCs in the blood 24 hours after injection 
and that a 3-day AMD3100 dosing regimen increased bone volume 84 days after injury in 
a murine femur fracture model [262].   We, however, were able to show that with 
biweekly injects of VPC01091, bone volume significantly increased as early as 8 weeks 
(56 days) (Figure 5.8C). Additionally, we found that VPC01091 induces more progenitor 
cells into circulation that with AMD3100 (Figure 5.1C).   
Systemically administered allogeneic MSCs are a promising therapeutic approach 
to prevent or ameliorate metabolic bone diseases, such as hypophosphatasia or 
osteoporosis.  Limited success has been reported involving MSC therapies to enhance 
skeletal mineralization and halt disease progression; healthy donor MSC survival and 
integration in bone is a challenge.  The treatment of a few patients with MSCs supported 
by myeloablation and bone marrow transplants resulted in some desired clinical 
outcomes, but only provided low levels of stromal cell engraftment in the bone [228, 263-
266]. Therefore, we hypothesized that mobilization of endogenous MSCs with 
VPC01091 could be combined with MSC transplantation to yield enhanced treatment of 
bone defects and metabolic bone diseases.  Our results demonstrate that VPC01091 does 
not obstruct donor MSC transplantation (Figure 5.10B). We plan to do further studies in 
order to determine if mobilizing endogenous MSCs with VPC01091 and combining with 
MSC transplantation aids in decreasing the negative effects of allogenic treatment that 
has been seen in some combination bone graft therapies [267-269].  
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We noted previously that VPC01091 and AMD3100 have different (and in many 
ways complimentary) mechanisms of action [96]. While VPC01091 indirectly affects 
CXCR4 by preventing its phosphorylation via S1PR3, AMD3100 directly binds to three 
acid residues in the main ligand-binding pocket [61, 270].  We found that LSK cells pre-
treated with VPC01091 had greater BM engraftment capacity in comparison to pre-
treated AMD3100 cells [96].  Consequently, Granero-Molto et al. and Osturu et al., states 
that the CXCR4/SDF-1 pathway is necessary for MSCs to home bone and then 
differentiate into osteoblasts [92, 93]. More CXCR4+ MSCs may be present in 
circulation after VPC01091 treatment (as we saw previously with HSPCs) than with 
AMD3100, allowing for more cells to migrate to the site of injury and enhance bone 
repair [96]. Moreover, as our data suggests that this treatment does not hinder 
engraftment of transplanted MSCs, (Figure 5.10B), we believe our approach strikes an 
important balance between transient mobilization signals to evacuate the niche and 
preservation of niche signaling elements to facilitate homing and engraftment into bone. 
Finding technologies that will effectively manage this compromise may be key to 
successful translation and treatment of skeletal diseases caused by errors in bone 
metabolism.   
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CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS  
6.1 Major Findings  
The work presented in this thesis represents a significant contribution to the field of 
sickle cell disease (SCD) by elucidating the under-characterized sickle bone phenotype of 
weakened biomechanical strength due to reduced trabecular and cortical bone, 
discovering cysteine cathepsins as a viable target to relegate bone loss, and establishing 
endogenous (mesenchymal stem cell) MSC mobilization as potential therapy for bone 
disorders. This work expands the understanding of the relationship between dysregulated 
sphingolipid metabolism in SCD and subsequent increased cathepsin activation; we 
identify methods in which this relationship can be utilized as a potential therapy for sickle 
bone disease (SBD) to promote bone growth and development. This thesis also 
demonstrates that modulating sphingolipid signaling increases bone repair.  
 In Aim 1, we characterize novel differences in bone development as well as bone 
architecture for the sickle Townes mouse model. We discovered that SBD leads to 
delayed proximal epiphyseal fusion and therefore stunted skeletal maturation and overall 
growth. Furthermore, we discovered that while cortical bone deficiency is present in both 
sexes, trabecular bone growth is impaired in SS females while increases with age in SS 
males. Interestingly, our work also displays that the sickle bone phenotype varies in the 
trabecular bone depending on the anatomical structure (e.g. femoral neck, distal 
epiphysis). For example, in female SS mice only the trabecular thickness (Tb.Th.) is 
reduced in the femoral neck, but in the distal epiphysis, the Tb.Th. as well as the bone 
tissue mineral density (BMD) was decreased. Through multivariate analysis we were able 
to determine that trabecular bone parameters had the most significant effect in separating 
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the sickle bone phenotype from normal and sickle trait, regardless of sex. Overall, we 
were able to determine that when characterizing the sickle bone phenotype, trabecular 
bone morphometry is the most important factor and should be depicted at various 
anatomical sites when investigating potential therapies for SBD.   
 In Aim 2, we show a connection between sphingolipid metabolism and increased 
cathepsin activity that leads to bone loss in SCD. We demonstrate that sphingosine 1-
phosphate (S1P) is increased in the blood of a sickle transgenic mouse model. We 
elucidate that increased S1P in the blood of our sickle mouse model causes for an 
increase in osteoclast progenitors (OPCs) in the bone marrow (BM) and subsequent 
increased bone resorption. This finding is further evident in the increased TRAP staining 
in sickle femurs as well as increased osteoclastogenesis from SS BM cells. Furthermore, 
we demonstrated that the dysregulated sphingolipid metabolism in SCD that produces 
more proinflammatory microparticles (MPs), also leads to increased osteoclast activity by 
amplifying the cathepsin K (cat K) activity of osteoclast precursors. Moreover, we 
discovered that cat K activity and production in SS osteoclasts is increased. We were able 
to connect this increase in cathepsin activity to the sickle bone phenotype that we 
characterized in Aim 1 by showing that cathepsin inhibition results in improved bone 
strength and cortical and trabecular bone growth in SCD.  Overall, we show a novel 
connection between sphingolipid metabolism and cathepsin activity that leads to the 
pathological bone resorption characteristic of SBD. 
 In Aim 3, we were able to demonstrate for the first time that S1P signaling could 
be utilized to mobilize MSCs into the peripheral blood (PB).  We prove that the 
antagonism of sphingosine 1-phosphate receptor 3 (S1PR3) through the drug VPC01091 
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increases the circulation of MSCs into the PB and thus leads to increased bone growth in 
the context of an orthopedic injury. With the administration of VPC01091, MSCs 
increased in circulation as early as 1.5 hours and remained in circulation at 24 hours. 
Through ectopic bone and cranial critical-defect models, we were able to demonstrate 
that treatment with VPC01091increases bone growth. These findings relay a potential 
treatment strategy to combat the bone loss characterized in SCD in Aim 1.   
6.2 Future Directions 
6.2.1 Utilization  of endogenous MSC mobilization to enhance bone regeneration 
in SCD 
We believe that mobilized autologous MSCs are a promising therapeutic approach 
to treat SBD.  Allogenic MSC therapy has yielded improvements in metabolic bone 
disorders such as hypophosphatasia and osteogenesis imperfecta [228, 263-266, 
271]. Although external MSC administration has been therapeutic, low and inconsistent 
rates of engraftment lead to poorer outcomes. In looking at autologous therapy for SBD, 
human SS MSCs did not have diminished osteogenic potential [23]. In one study, MSCs 
harvested from the iliac crest of sickle patients suffering from early stage osteonecrosis 
(ON) were able to delay the progression of bone death in the femoral head for 5 years 
[228, 263-266, 271]. However, in more advanced stages of ON, there is more bone loss, 
and thus more stem cells are needed in order to fully regenerate the bone than can be 
safely harvested from patients at one time. Therefore, ex vivo expansion of MSCs would 
be necessary, a process which takes anywhere from 4-6 weeks and decreases the cells’ 
mineralization capacity [249, 252]. It would be interesting to see the effects of utilizing 
VPC01091 to mobilize endogenous MSCs on bone morphology and growth in our sickle 
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Townes mouse model as an alternative therapy for SBD. With the occlusions that occur 
in the microvasculature of the BM due to the sickling of erythrocytes, it is possible that 
poor circulation of MSCs to the site of injury, as presumed by Lebouvier et al., is also 
aiding in the bone loss in SCD that we characterized in Aim 1. We have shown in Aim 3 
that the administration of VPC01091 leads to an increase in circulating MSCs as well an 
increase in bone growth in a bone defect model. Furthermore, this thesis work highlights 
an important role for S1PRs in MSC niche occupancy and trafficking that can be 
harnessed for rapid endogenous MSC mobilization and homing into the diseased osseous 
tissues of sickle bone for subsequent bone regeneration.  
6.2.2 Utilization of acid SMase inhibition to reduce RBC MPs in order to attenuate 
bone loss in SCD   
 We have shown previously that acid sphingomyelinase (SMase) inhibition with 
the tricyclic antidepressant amitriptyline reduces red blood cell (RBC)-derived MPs in 
vitro as well as in wild type mice [10].  We have established in Aim 2 that RBC MPs 
increase the activity of cat K, an enzyme that aids in bone resorption, in SS and AA 
peripheral blood mononuclear cells (PBMCs). Additionally, others have shown that 
sphingosine kinase 1 (SK1) inhibition leads to less sickling of RBCs [12]. Reduced RBC 
sickling would lead to decreased vaso-occulsions in the microvasculature of bone and 
thus diminished bone loss. Acid SMase converts sphingomyelin (SM) into ceramide 
(Cer), which can then be converted into sphingosine (So) in order to be phosphorylated 
by SK. Acid SMase therefore is an upstream target of SK. Therefore, we find it 
imperative that acid SMase inhibition be explored as potential treatment in reducing 
proteolytic MPs, RBC sickling, and thus subsequent bone loss in SCD.  
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6.2.3 Investigation of the role of MSC sphingolipid metabolism in osteoblast 
differentiation in SBD pathology  
In Aim 2 we have shown that SS MSCs have a different sphingolipid profile in 
comparison to AA and AS MSCs. Sphingolipids have been shown to be tissue specific 
and even alter during cellular processes such as differentiation [194, 195]. We have 
demonstrated that sphingolipid metabolism is dysregulated in SS RBCs, blood, and 
plasma [10]. Changes in RBC membrane morphology drive alterations in the activity of 
sphingolipid-metabolizing enzymes; increases in SK1 and subsequent elevated blood 
sphingosine 1-phosphate (S1P) increases the sickling and membrane distortions in SS 
RBCs [10, 12]. Changes in MSC morphology have been linked to their osteogenic 
potential/mineralization capacity [252, 272, 273]. Additionally, MSC osteoblast 
differentiation is enhanced with S1P and FTY720 treatment as well as their morphology 
is altered [63, 64, 181]. In the transgenic sickle Townes model, MSCs isolated from SS 
MSCs have a lower incidence of osteoblast differentiation when compared to AA MSCs; 
additionally, the mRNA expression of osteogenic genes osterix, RUNX2, osteocalcin, 
and osteonectin are decreased in SS mice [134, 137]. With SCD pathology including 
femoral and vertebral infarcts, ON, osteoporosis, and increased risk of bone fracture, 
there is a need to discover the mechanism behind this decrease in SS MSCs progression 
towards osteogenic lineage [2, 4, 274]. We believe that studies should be conducted to 
test if the difference in sphingolipid profile of SS MSCs causes reduced osteogenic 
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